Chromosome 3q29 Microdeletion Syndrome

Genetic MONDO:0012269 Pathograph 18 Show in embeddings browser Chromosomal deletion syndrome Neurodevelopmental disorder

3q29 deletion syndrome is a recurrent ~1.6 Mb subtelomeric copy-number disorder, generated by non-allelic homologous recombination between the low-copy repeats that flank the interval and usually arising de novo. Hemizygous loss of the ~21 protein-coding genes inside it produces a broad neurodevelopmental and neuropsychiatric phenotype — mild-to-moderate intellectual disability, autism spectrum disorder, ADHD, anxiety, executive-function and graphomotor deficits — together with a systemic burden that is easy to underweight: gastrointestinal symptoms are actually the commonest manifestation, and congenital heart defects the most severe. Two things make this entry worth curating carefully rather than filing as "another recurrent CNV". First, the schizophrenia risk is exceptional. The deletion carries at least a 40-fold increase in risk, one of the largest effect sizes known anywhere in the genetics of schizophrenia, and psychosis can begin earlier than in the general population. Second, no single gene in the interval has been shown to be necessary and sufficient. Single-gene knockouts of the leading candidates do not reproduce the syndrome; what the functional work supports instead is combinatorial haploinsufficiency, with NCBP2 acting as a broad enhancer of the other genes' phenotypes and PAK2 contributing to a mitochondrial-metabolic deficit conserved from human organoids to mouse cortex. The entry models that as a genuine multi-gene node rather than nominating a driver the evidence does not support.

Ask OpenScientist

Ask a research question about Chromosome 3q29 Microdeletion Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
20
Phenotypes
2
Gaps
18
Pathograph
3
Genes
6
Medical Actions
2
Differentials
4
Models
8
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant, typically de novo HP:0000006
The deletion is dominant in transmission but usually arises de novo, so most probands are simplex. Sibling recurrence risk is low but not zero because of possible parental mosaicism; an affected individual transmits the deletion to half their offspring.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:27656750 SUPPORT Human Clinical
"3q29 recurrent deletion is an autosomal dominant disorder typically caused by a de novo deletion."
GeneReviews states the mode of inheritance and its usual de novo origin.
PMID:27656750 SUPPORT Human Clinical
"If the proband represents a simplex case (i.e., a single affected family member) and neither parent has the 3q29 recurrent deletion or a balanced chromosome rearrangement, the recurrence risk to sibs is low (presumed to be <1%) but greater than that of the general population because of the..."
Source of the recurrence-risk statement, including the mosaicism caveat.
?

Discussions and Knowledge Gaps

2
Which gene or combination of genes in the 3q29 interval is responsible for the neurodevelopmental and psychiatric phenotype?
KNOWLEDGE GAP q3q29_driver_gene_attribution
Attached to
pathophysiology#Combinatorial Haploinsufficiency Across the 3q29 Interval
Two decades after the syndrome was described, no gene in the interval has been shown to be necessary and sufficient, and single-gene knockouts of the leading candidates do not reproduce it. The evidence points instead at combinatorial haploinsufficiency, with NCBP2 acting as an enhancer of other genes' effects and PAK2 contributing to a measured metabolic deficit. This gap is what stops the entry nominating a driver, and it is not merely academic: a therapeutic strategy aimed at one gene presupposes an answer that does not exist. Note also that the interval's genes are functionally heterogeneous — synaptic scaffolding, actin regulation, mRNA cap binding, ubiquitination and SUMOylation — so "combinatorial" here does not yet mean "converging on one pathway".
Proposed experiments
Single-gene dosage restoration in isogenic 3q29 deletion organoids
q3q29_single_gene_rescue_in_isogenic_organoids
Restore each interval gene individually and in defined combinations in the isogenic deletion organoid background, and test which restorations rescue the mitochondrial and transcriptomic phenotypes. A single-gene rescue would identify a driver; a requirement for combinations would confirm the combinatorial model directly rather than by inference from knockdown screens.
Show evidence (3 references)
PMID:32053595 SUPPORT Model Organism
"Despite its importance towards neurodevelopment, the role of individual genes, genetic interactions, and disrupted biological mechanisms underlying the deletion have not been thoroughly characterized."
States the gap directly.
DOI:10.1186/s11689-026-09696-y SUPPORT Other
"Hemizygosity of this set of 22 protein-coding genes significantly increases risk for schizophrenia and autism spectrum disorders among other neurodevelopmental conditions, but it is not known which genes in this CNV interval are responsible for these phenotypes."
A review dedicated to exactly this question, stating that it remains open.
DOI:10.1186/s11689-026-09696-y SUPPORT Other
"Our analysis reveals that ubiquitination/SUMOylation stands out among processes potentially compromised due to compound haploinsufficiency of four 3q29Del genes"
Nominates a candidate converging pathway, which is the most concrete current answer to the gap and is recorded as such rather than adopted as the mechanism.
Does antipsychotic-reversible prepulse-inhibition impairment in the syntenic mouse tell us anything about the psychosis risk that defines this syndrome in humans?
HUMAN MODEL MISMATCH q3q29_psychosis_model_gap
Attached to
pathophysiology#Cortical Excitation-Inhibition Imbalance
The mouse work is genuinely strong on its own terms — construct validity by design, a restricted cortical hyperactivation phenotype, reduced parvalbumin expression, and a behavioural deficit that antipsychotics reverse. But prepulse inhibition is a sensorimotor gating measure, not psychosis, and the drug reversal demonstrates that the proxy is pharmacologically responsive rather than that the model captures the human illness. The mismatch matters here more than usual because the >40-fold schizophrenia risk is the syndrome's signature finding, so the phenotype we most want a model for is precisely the one no rodent can carry. The cortical excitation-inhibition node is curated at PROVISIONAL confidence for this reason.
Proposed experiments
Human cortical excitation-inhibition measures in deletion carriers
q3q29_human_cortical_circuit_measures
Apply non-invasive measures of cortical excitation-inhibition balance — for example magnetic resonance spectroscopy of GABA and glutamate, or TMS-EEG-derived cortical inhibition — in deletion carriers with and without psychotic symptoms, to test whether the imbalance the mouse shows has a human correlate that tracks psychiatric outcome.
Show evidence (1 reference)
PMID:31216562 SUPPORT Model Organism
"These findings are reminiscent of the growth defects and neuropsychiatric behavioral phenotypes in patients with 3q29 deletion syndrome and exemplify that the mouse model achieves some part of face validity and predictive validity."
The authors' own hedged validity claim, quoted because the hedge is the point.
⚙

Pathophysiology

6
Non-Allelic Homologous Recombination at 3q29 Low-Copy Repeats
The initiating event, and the reason the deletion is recurrent rather than private. Two nearly identical low-copy repeats flank the interval; misalignment between them during meiosis and unequal crossing-over excises the intervening sequence, producing near-identical breakpoints in unrelated patients. The reciprocal product of the same event is the 3q29 microduplication, which is a distinct and generally milder disorder.
recombinational repair GO:0000725 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal recombinational repair (GO:0000725). GO:0000725 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Combinatorial Haploinsufficiency Across the 3q29 Interval The excision leaves one functional copy of every gene in the interval.
Show evidence (2 references)
PMID:15918153 SUPPORT Human Clinical
"The presence of two nearly identical low-copy repeat sequences in BAC clones on each side of the deletion breakpoint suggests that nonallelic homologous recombination is the likely mechanism of disease causation in this syndrome."
Original identification of the recombination mechanism.
PMID:15918153 SUPPORT Human Clinical
"The microdeletion is approximately 1.5 Mb in length, with molecular boundaries mapping within the same or adjacent bacterial artificial chromosome (BAC) clones at either end of the deletion in all patients."
Documents the near-identical breakpoints that make the deletion recurrent.
Combinatorial Haploinsufficiency Across the 3q29 Interval
Hemizygosity for the ~21 protein-coding genes in the interval. The load-bearing curatorial point is negative: no single gene has been shown to be necessary and sufficient for the syndrome, and this node deliberately does not nominate one. The leading candidates are DLG1 and PAK2, autosomal paralogues of the X-linked intellectual disability genes DLG3 and PAK3, and NCBP2, which behaves as a broad enhancer of the other genes' phenotypes rather than as a driver in its own right. A pairwise interaction screen across 314 combinations of 14 homologs found dozens of interactions and traced the NCBP2 effect to increased apoptosis, which was rescued by apoptosis inhibitors — evidence that the mechanism is interaction between genes in the interval, not the failure of any one of them.
DLG1 hgnc:2900 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves DLG1 (hgnc:2900). hgnc:2900 is a gene from the HUGO Gene Nomenclature Committee. PAK2 hgnc:8591 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PAK2 (hgnc:8591). hgnc:8591 is a gene from the HUGO Gene Nomenclature Committee. NCBP2 hgnc:7659 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NCBP2 (hgnc:7659). hgnc:7659 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context functional_impact_category: LOSS_OF_FUNCTION
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Drosophila and Xenopus 3q29 homolog knockdown panel Drosophila melanogaster and Xenopus laevis perturbs Systematic pairwise perturbation identified 44 interactions between 3q29 gene homolog pairs and 34 with other neurodevelopmental genes, with NCBP2 emerging as a broad enhancer acting through apoptosis.
Downstream
Mitochondrial and Energy-Metabolism Dysregulation Reduced dosage across the interval, with a demonstrated PAK2 contribution, converges on mitochondrial function and metabolic flexibility.
Cortical Excitation-Inhibition Imbalance Reduced gene dosage produces cortical hyperactivity and reduced parvalbumin-interneuron marker expression in the mouse model; the steps between are not established.
Posterior Fossa and Cerebellar Maldevelopment The cerebellum and posterior fossa are disproportionately affected, but no specific gene in the interval has been tied to that regional vulnerability.
Show evidence (5 references)
PMID:15918153 SUPPORT Human Clinical
"The deletion encompasses 22 genes, including PAK2 and DLG1, which are autosomal homologues of two known X-linked mental retardation genes, PAK3 and DLG3."
Identifies the two original candidate genes and the paralogy argument for them.
PMID:32053595 SUPPORT Model Organism
"Interestingly, NCBP2 homologs in Drosophila (Cbp20) and X. laevis (ncbp2) enhanced the phenotypes of homologs of the other 3q29 genes, leading to significant increases in apoptosis that disrupted cellular organization and brain morphology."
The enhancer role of NCBP2 and its apoptotic readout, which is why this node is combinatorial rather than single-gene.
PMID:32053595 SUPPORT Model Organism
"Overall, our study suggests that NCBP2-mediated genetic interactions within the 3q29 region disrupt apoptosis and cell cycle mechanisms during development."
States the interaction-based mechanism this node encodes.
+ 2 more references
Mitochondrial and Energy-Metabolism Dysregulation
The best-supported molecular consequence, and notable for how it was established: single-cell transcriptomes from isogenic human cortical organoids and from mouse isocortex converged independently on mitochondrial function and energy metabolism, and the signature was then confirmed at the level of oxidative-phosphorylation complex protein expression and functional assays. The functional deficit is described as a lack of metabolic flexibility rather than a flat loss of respiratory capacity, and PAK2 is identified as a contributor. The cross-species convergence is what raises this above a single transcriptomic observation.
glutamatergic neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology.
PAK2 hgnc:8591 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PAK2 (hgnc:8591). hgnc:8591 is a gene from the HUGO Gene Nomenclature Committee.
oxidative phosphorylation GO:0006119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated oxidative phosphorylation (GO:0006119). GO:0006119 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Experimental models
Isogenic 3q29 deletion human cortical organoids ORGANOID The human half of the cross-species convergence on mitochondrial function and energy metabolism in developing cortical tissue.
Animal models
CRISPR-engineered 3q29 deletion mouse Mouse recapitulates Perinatal isocortex from this model contributed the mouse half of the cross-species convergence on mitochondrial and energy-metabolism pathways.
Downstream
Neurodevelopmental and Neuropsychiatric Phenotype Metabolic constraint on developing cortical neurons is proposed to contribute to the neurodevelopmental outcome; the connecting steps are not established.
Show evidence (2 references)
PMID:37585521 SUPPORT In Vitro
"Systematic pathway analysis implicated dysregulation of mitochondrial function and energy metabolism."
The transcriptomic finding in isogenic organoids and mouse isocortex.
PMID:37585521 SUPPORT In Vitro
"These molecular signatures were supported by analysis of oxidative phosphorylation protein complex expression in mouse brain and assays of mitochondrial function in engineered cell lines, which revealed a lack of metabolic flexibility and a contribution of the 3q29 gene PAK2."
Orthogonal protein-level and functional confirmation, and the PAK2 attribution.
Cortical Excitation-Inhibition Imbalance
In the syntenic mouse model, whole-brain imaging after a behavioural task showed neuronal hyperactivation that was strikingly exaggerated but spatially restricted rather than global, accompanied by reduced parvalbumin expression in cortex. That combination — excess excitatory activity with reduced inhibitory interneuron marker expression — is the standard shape of an excitation-inhibition imbalance, and it is the cellular phenotype the mouse work offers for the psychiatric arm of the syndrome. It is a model-organism finding; no equivalent human cortical measurement exists.
GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
chemical synaptic transmission GO:0007268 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology. ↕ DYSREGULATED
neocortex UBERON:0001950 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in neocortex (UBERON:0001950). UBERON:0001950 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
3q29 deletion (Df/+) mouse Mouse recapitulates Regionally restricted cortical neuronal hyperactivation with reduced parvalbumin expression, plus impaired prepulse inhibition that is reversed by antipsychotics.
Downstream
Neurodevelopmental and Neuropsychiatric Phenotype Cortical circuit imbalance is the proposed substrate for the psychiatric phenotype, on the strength of model-organism evidence only.
Show evidence (2 references)
PMID:31216562 SUPPORT Model Organism
"We further elucidated the cellular phenotypes of neuronal hyperactivation and the reduction of parvalbumin expression in the cortex of Df/+ mice."
The two cellular measurements that constitute this node.
PMID:31216562 SUPPORT Model Organism
"Unbiased whole-brain imaging revealed that neuronal hyperactivation after a behavioral task was strikingly exaggerated in a restricted region of the cortex of Df/+ mice."
Establishes that the hyperactivation is regionally restricted rather than global.
Posterior Fossa and Cerebellar Maldevelopment
A structural signature specific enough to be a candidate biomarker. Quantitative MRI shows smaller cerebellar cortex volumes and, in the opposite direction, larger cerebellar white matter volumes, together with elevated rates of posterior fossa arachnoid cysts and mega cisterna magna. The dissociation within that list matters: cerebellar grey and white matter volumes track visual perception, visual-motor integration and IQ, whereas the cystic malformations — the findings most likely to be flagged on a clinical read — showed no behavioural association at all. Reporting the cyst without the volumetrics would therefore be reporting the part that does not predict anything.
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (3 references)
PMID:38744992 SUPPORT Human Clinical
"3q29Del participants had smaller cerebellar cortex volumes than controls, before and after correction for intracranial volume (ICV)."
The primary volumetric finding.
PMID:38744992 SUPPORT Human Clinical
"3q29Del participants also had larger cerebellar white matter volumes than controls following ICV-correction and displayed elevated rates of posterior fossa arachnoid cysts and mega cisterna magna findings independent of cerebellar volume."
The white-matter and cystic findings, and their independence from cerebellar volume.
PMID:38744992 SUPPORT Human Clinical
"Cerebellar white matter and subregional gray matter volumes were associated with visual-perception and visual-motor integration skills as well as IQ, while cystic/cyst-like malformations yielded no behavioral link."
The dissociation between the volumetric findings, which predict function, and the cystic findings, which do not.
Neurodevelopmental and Neuropsychiatric Phenotype
The clinical output. Neurodevelopmental burden dominates — intellectual disability, autism spectrum disorder, executive-function deficits and graphomotor weakness — and psychiatric illness accumulates across the lifespan, with anxiety and ADHD common in childhood and psychosis emerging later, at an age that can precede the usual population onset. The cognitive profile has a specific shape rather than being uniformly depressed: verbal ability typically exceeds non-verbal, which can mask the non-verbal deficit and lead to overestimation of overall ability.
glutamatergic neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology.
Show evidence (3 references)
PMID:33564151 SUPPORT Human Clinical
"Neurodevelopmental phenotypes represent a significant burden and include intellectual disability (34%), autism spectrum disorder (38%), executive function deficits (46%), and graphomotor weakness (78%)."
Quantifies the neurodevelopmental component from a systematic phenotyping protocol.
PMID:33564151 SUPPORT Human Clinical
"Psychiatric illness manifests across the lifespan with psychosis prodrome (15%), psychosis (20%), anxiety disorders (40%), and attention deficit-hyperactivity disorder (ADHD) (63%)."
Quantifies the psychiatric component across the lifespan.
PMID:35297118 SUPPORT Human Clinical
"Two-thirds of individuals with the deletion will exhibit significant strength in verbal ability; this may mask deficits in non-verbal reasoning, leading to an overestimation of overall ability."
Establishes the verbal-over-non-verbal profile and its clinical consequence.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Chromosome 3q29 Microdeletion Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

20
Cardiovascular 1
Congenital Heart Defect OCCASIONAL Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"The most severe manifestations were congenital heart defects (25%) and the most common were gastrointestinal symptoms (81%)."
Gives the 25% figure and the severity ranking.
PMID:27656750 SUPPORT Human Clinical
"ocular issues, dental anomalies, and congenital heart defects (especially patent ductus arteriosus)."
Names congenital heart defects among the common findings and identifies patent ductus arteriosus as the lesion most often singled out.
Digestive 3
Gastrointestinal Symptoms VERY_FREQUENT Abnormality of the gastrointestinal tract HP:0011024 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the gastrointestinal tract (HP:0011024). HP:0011024 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"The most severe manifestations were congenital heart defects (25%) and the most common were gastrointestinal symptoms (81%)."
Gives the 81% figure and the explicit statement that GI symptoms are the commonest manifestation. The term is bound at the umbrella level because 81% is the rate for gastrointestinal symptoms as a class, not for any single one.
PMID:27656750 SUPPORT Human Clinical
"Other common findings are failure to thrive and feeding problems in infancy that persist into childhood, gastrointestinal disorders (including constipation and gastroesophageal reflux disease [GERD])"
Enumerates the specific gastrointestinal manifestations.
Gastroesophageal Reflux FREQUENT HP:0002020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Other common findings are failure to thrive and feeding problems in infancy that persist into childhood, gastrointestinal disorders (including constipation and gastroesophageal reflux disease"
GeneReviews names GERD among the common gastrointestinal findings.
Constipation FREQUENT HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Other common findings are failure to thrive and feeding problems in infancy that persist into childhood, gastrointestinal disorders (including constipation and gastroesophageal reflux disease"
GeneReviews names constipation among the common gastrointestinal findings.
Ear 1
Recurrent Otitis Media OCCASIONAL HP:0000388 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Otitis media (HP:0000388). HP:0000388 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27656750 SUPPORT Human Clinical
"routine management of musculoskeletal issues, GERD, strabismus, dental issues, congenital heart defects, recurrent ear infections, and epistaxis"
Names recurrent ear infections among the manifestations requiring routine management.
PMID:33564151 SUPPORT Human Clinical
"had recurrent ear infections, and three subjects required surgery."
Systematic-cohort confirmation, including that a subset required surgical management.
Eye 1
Ocular Involvement FREQUENT Strabismus HP:0000486 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Strabismus (HP:0000486). HP:0000486 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:27656750 SUPPORT Human Clinical
"ocular issues, dental anomalies, and congenital heart defects (especially patent ductus arteriosus)."
GeneReviews names ocular issues among the common findings.
PMID:27656750 SUPPORT Human Clinical
"routine management of musculoskeletal issues, GERD, strabismus, dental issues, congenital heart defects, recurrent ear infections, and epistaxis"
Identifies strabismus specifically as a managed manifestation.
PMID:33564151 SUPPORT Human Clinical
"had a symptom or diagnosis related to the eye. The most common ocular phenotype was strabismus"
Systematic-cohort confirmation that ocular involvement is common and that strabismus is its commonest form.
Head and Neck 1
Dental Anomalies FREQUENT Abnormality of the dentition HP:0000164 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the dentition (HP:0000164). HP:0000164 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27656750 SUPPORT Human Clinical
"ocular issues, dental anomalies, and congenital heart defects (especially patent ductus arteriosus)."
GeneReviews names dental anomalies among the common findings.
PMID:33564151 SUPPORT Human Clinical
"Dental anomalies were reported in 41%"
Gives the cohort figure underlying the FREQUENT band.
Nervous System 8
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
DOI:10.3389/frcha.2026.1823061 SUPPORT Human Clinical
"3q29 deletion syndrome is a rare genomic disorder characterized by a broad spectrum of neurodevelopmental and psychiatric manifestations, including developmental delay (DD), intellectual disability (ID), autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and a..."
Names developmental delay explicitly as a characteristic manifestation. Supports the association, not a rate.
PMID:27656750 SUPPORT Human Clinical
"3q29 recurrent deletion is characterized by neurodevelopmental and/or psychiatric manifestations including mild-to-moderate intellectual disability (ID), autism spectrum disorder (ASD), anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), executive function deficits, graphomotor..."
GeneReviews frames the disorder as defined by its neurodevelopmental manifestations. PARTIAL because the list names intellectual disability and the specific cognitive deficits rather than global developmental delay as such.
Intellectual Disability FREQUENT Mild intellectual disability HP:0001256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild intellectual disability (HP:0001256). HP:0001256 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"Neurodevelopmental phenotypes represent a significant burden and include intellectual disability (34%), autism spectrum disorder (38%), executive function deficits (46%), and graphomotor weakness (78%)."
Gives the 34% figure underlying the FREQUENT band.
PMID:35297118 SUPPORT Human Clinical
"Mean full scale IQ was 73 (range 40-99)."
Quantifies the cognitive range in a standardized-protocol cohort.
Autism Spectrum Disorder FREQUENT Autistic behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:31346402 SUPPORT Human Clinical
"3q29Del cases report a higher prevalence of autism diagnoses versus the general population (29.0% vs. 1.47%, p < 2.2E- 16)."
Quantifies both the rate and the enrichment over population baseline.
PMID:31346402 SUPPORT Human Clinical
"Finally, cases show a distinct constellation of ASD features on the SRS as compared to idiopathic ASD, with substantially elevated Restricted Interests and Repetitive Behaviors, but only mild impairment in Social Motivation."
Establishes the qualitative distinctiveness of the autism phenotype here.
PMID:31346402 SUPPORT Human Clinical
"Notably, 3q29 deletion confers a greater influence on risk for ASD in females (OR = 41.8, p = 4.78E- 05) than in males (OR = 24.6, p = 6.06E- 09); this is aligned with the reduced male:female bias from 4:1 in the general population to 2:1 in our study sample."
Documents the attenuated male bias and the sex-differential effect size.
Psychosis and Schizophrenia OCCASIONAL HP:0000709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Show evidence (7 references)
PMID:33564151 SUPPORT Human Clinical
"Psychiatric illness manifests across the lifespan with psychosis prodrome (15%), psychosis (20%), anxiety disorders (40%), and attention deficit-hyperactivity disorder (ADHD) (63%)."
Gives the 20% psychosis figure underlying the OCCASIONAL band.
PMID:37585521 SUPPORT Human Clinical
"Hemizygous loss of this set of genes is associated with at least a 40-fold increase in risk for SCZ"
Secondary statement of the relative risk, in the paper that established the mitochondrial mechanism.
PMID:26055425 SUPPORT Human Clinical
"The results of this analysis indicate that the 3q29 deletion confers a 41.1-fold increased risk for SZ"
The primary meta-analytic source for the effect size, cited alongside the secondary statement rather than in place of it.
+ 4 more references
Attention Deficit Hyperactivity Disorder FREQUENT HP:0007018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Attention deficit hyperactivity disorder (HP:0007018). HP:0007018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33564151 SUPPORT Human Clinical
"Psychiatric illness manifests across the lifespan with psychosis prodrome (15%), psychosis (20%), anxiety disorders (40%), and attention deficit-hyperactivity disorder (ADHD) (63%)."
Gives the 63% ADHD figure underlying the FREQUENT band.
Anxiety Disorder FREQUENT HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:33564151 SUPPORT Human Clinical
"Psychiatric illness manifests across the lifespan with psychosis prodrome (15%), psychosis (20%), anxiety disorders (40%), and attention deficit-hyperactivity disorder (ADHD) (63%)."
Gives the 40% anxiety figure underlying the FREQUENT band.
PMID:31346402 SUPPORT Human Clinical
"Cases also report increased frequency of generalized anxiety disorder compared to controls (28.0% vs. 6.2%, p = 0.001)"
Independent case-control confirmation from the registry cohort.
PMID:38216835 SUPPORT Human Clinical
"Individuals with 3q29del showed significantly elevated behavioral and developmental impairment relative to controls across CBCL/ABCL domains."
Instrument-based confirmation of elevated behavioural burden against a control group.
Delayed Speech and Language Development FREQUENT HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27656750 SUPPORT Human Clinical
"Early speech and language therapy to address speech delays; physical/occupational therapy as needed to address motor issues"
GeneReviews management guidance presupposes speech delay as a standard feature.
PMID:35297118 SUPPORT Human Clinical
"The age at which a child first spoke two-word phrases was strongly associated with measures of verbal ability (P value 2.56e-07)."
Supports the prognostic significance of the speech delay.
Cerebellar Hypoplasia HP:0001321 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar hypoplasia (HP:0001321). HP:0001321 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"Neuroimaging revealed structural anomalies of the posterior fossa, but on neurological exam study subjects displayed only mild or moderate motor vulnerabilities."
Documents posterior fossa anomalies alongside the comparatively mild motor examination.
PMID:38744992 SUPPORT Human Clinical
"3q29Del participants had smaller cerebellar cortex volumes than controls, before and after correction for intracranial volume (ICV)."
Quantitative confirmation of reduced cerebellar cortical volume.
Growth 1
Failure to Thrive FREQUENT HP:0001508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Other common findings are failure to thrive and feeding problems in infancy that persist into childhood, gastrointestinal disorders (including constipation and gastroesophageal reflux disease"
GeneReviews names failure to thrive and its persistence.
Other 4
Executive Function Deficits FREQUENT
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"Neurodevelopmental phenotypes represent a significant burden and include intellectual disability (34%), autism spectrum disorder (38%), executive function deficits (46%), and graphomotor weakness (78%)."
Gives the 46% figure underlying the FREQUENT band.
PMID:39365000 SUPPORT Human Clinical
"Prior work by our team identified clinically significant executive function (EF) deficits in 47% of individuals with 3q29del; however, the nuances of EF in this population have not been described."
Independent confirmation of the rate, from the study dedicated to the domain.
Graphomotor Weakness FREQUENT
Show evidence (1 reference)
PMID:33564151 SUPPORT Human Clinical
"Neurodevelopmental phenotypes represent a significant burden and include intellectual disability (34%), autism spectrum disorder (38%), executive function deficits (46%), and graphomotor weakness (78%)."
Gives the 78% figure underlying the FREQUENT band.
Musculoskeletal Findings VERY_FREQUENT Abnormality of the musculoskeletal system HP:0033127 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the musculoskeletal system (HP:0033127). HP:0033127 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33564151 SUPPORT Human Clinical
"Physical examination revealed a high proportion of musculoskeletal findings (81%)."
Gives the 81% figure underlying the VERY_FREQUENT band.
PMID:15918153 SUPPORT Human Clinical
"Autism, gait ataxia, chest-wall deformity, and long and tapering fingers were noted in at least two of six patients."
Documents the specific musculoskeletal features in the original series.
Mild Facial Dysmorphism FREQUENT
Show evidence (1 reference)
PMID:15918153 SUPPORT Human Clinical
"The phenotype includes mild-to-moderate mental retardation, with only slightly dysmorphic facial features that are similar in most patients: a long and narrow face, short philtrum, and high nasal bridge."
Describes both the specific features and their mildness.
🧬

Genetic Associations

3
3q29 recurrent 1.6 Mb deletion (Genetic Mutation)
Gene: DLG1 hgnc:2900 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is DLG1 (hgnc:2900). hgnc:2900 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal dominant, typically de novo
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"The diagnosis of the 3q29 recurrent deletion is established by identification of a heterozygous 1.6-Mb deletion at the approximate position of chr3:195998129-197623129 in the reference genome (NCBI Build 38)."
Defines the deletion by coordinates, which is what the diagnosis rests on.
PAK2 (Disease-associated)
Gene: PAK2 hgnc:8591 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PAK2 (hgnc:8591). hgnc:8591 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: COOPERATING
Show evidence (1 reference)
PMID:37585521 SUPPORT In Vitro
"These molecular signatures were supported by analysis of oxidative phosphorylation protein complex expression in mouse brain and assays of mitochondrial function in engineered cell lines, which revealed a lack of metabolic flexibility and a contribution of the 3q29 gene PAK2."
The functional attribution that justifies the COOPERATING classification.
NCBP2 (Disease-associated)
Gene: NCBP2 hgnc:7659 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NCBP2 (hgnc:7659). hgnc:7659 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER
Show evidence (1 reference)
PMID:32053595 SUPPORT Model Organism
"Interestingly, NCBP2 homologs in Drosophila (Cbp20) and X. laevis (ncbp2) enhanced the phenotypes of homologs of the other 3q29 genes, leading to significant increases in apoptosis that disrupted cellular organization and brain morphology."
Establishes the enhancer/modifier role.
💊

Medical Actions

6
Early Speech and Language Therapy
Action: Speech Language TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Speech Language Therapy (NCIT:C159273). NCIT:C159273 is a clinical intervention from the NCI Thesaurus. NCIT:C159273
The earliest recommended intervention, targeting the speech delay that is both common and prognostically informative.
Target Phenotypes: Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Early speech and language therapy to address speech delays; physical/occupational therapy as needed to address motor issues"
GeneReviews management guidance naming speech therapy first.
Physical and Occupational Therapy
Action: Physical TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Physical Therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. NCIT:C15302
Directed at motor issues and at the visual-motor integration and graphomotor weakness that are among the most consistent functional deficits.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Early speech and language therapy to address speech delays; physical/occupational therapy as needed to address motor issues"
GeneReviews management guidance for the motor domain.
Psychiatric Care and Cognitive Behavioural Therapy
Action: Behavioral CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Behavioral Counseling (NCIT:C181743). NCIT:C181743 is a clinical intervention from the NCI Thesaurus. NCIT:C181743
Care by a child psychiatrist or psychologist with explicit transfer to adult services, plus cognitive behavioural therapy for social disability and anxiety. The lifespan framing is the point: the psychiatric risk in this syndrome does not end at paediatric discharge, it changes character, with psychosis risk rising as anxiety and ADHD are already established.
Target Phenotypes: Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"care by a child psychiatrist/psychologist as needed for neuropsychiatric disorders with transfer of care to an adult psychiatrist when appropriate; cognitive behavioral therapy to address social disability and/or anxiety"
GeneReviews guidance including the transition-of-care element.
Symptomatic Pharmacotherapy for Anxiety, ADHD or Psychosis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Medication is symptomatic. There is no disease-modifying or locus-directed therapy, and nothing in the literature reviewed proposes one.
Target Phenotypes: Psychosis HP:0000709 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"medication as needed for anxiety, ADHD, or psychosis; standard treatment of seizures"
GeneReviews guidance for symptomatic pharmacotherapy.
Structured Multisystem Surveillance
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
A defined surveillance schedule rather than a therapy, and worth curating separately because the schedule is what converts a list of associated findings into actionable care: developmental progress, growth, nutrition and feeding at every visit; annual neuropsychiatric and scoliosis assessment; annual ophthalmology; dental examination every six months.
Show evidence (2 references)
PMID:27656750 SUPPORT Human Clinical
"Surveillance: At each visit: monitor developmental progress, educational needs, growth, nutrition, and feeding; assess for seizures, gastrointestinal issues, otitis, enuresis, and/or sleep issues."
The per-visit surveillance content.
PMID:27656750 SUPPORT Human Clinical
"Annual assessment for neuropsychiatric manifestations and scoliosis; annual ophthalmology examination"
The annual surveillance content, including the psychiatric assessment that the early-onset psychosis risk motivates.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counselling covers a recurrence risk structure that is unusual for a dominant disorder: because the deletion is typically de novo, sibling recurrence risk is below 1% yet above population baseline because of possible parental mosaicism, while an affected individual's own offspring risk is 50%.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"Each child of an individual with the 3q29 recurrent deletion has a 50% chance of inheriting the deletion."
The offspring risk figure counselling communicates.
🔬

Diagnosis

2
Chromosomal Microarray
The deletion is submicroscopic and invisible on conventional karyotype, so detection requires chromosomal microarray or a targeted copy-number method (FISH, MLPA, qPCR). Diagnosis is by identification of the heterozygous 1.6 Mb deletion at the recurrent coordinates.
Show evidence (1 reference)
PMID:27656750 SUPPORT Human Clinical
"The diagnosis of the 3q29 recurrent deletion is established by identification of a heterozygous 1.6-Mb deletion at the approximate position of chr3:195998129-197623129 in the reference genome (NCBI Build 38)."
States the diagnostic standard and the coordinates.
Psychiatric and Neurodevelopmental Assessment
Formal assessment is recommended for every individual with the deletion, not only those who look impaired — a point with real consequences, because cognitive ability does not predict psychiatric burden here. Someone with an IQ in the normal range carries the same requirement for behavioural evaluation as anyone else with the deletion. Autism evaluation in particular is argued to be standard of care, since autistic features are present in many individuals who do not carry an autism diagnosis.
Show evidence (2 references)
PMID:35297118 SUPPORT Human Clinical
"Cognitive ability is not a strong indicator of other neurodevelopmental or psychiatric impairment; thus, individuals with 3q29 deletion syndrome who exhibit IQ scores within the normal range should receive all recommended behavioural evaluations."
The explicit recommendation, and the reason for it.
PMID:31346402 SUPPORT Human Clinical
"Our study implies that ASD evaluation should be the standard of care for individuals with 3q29Del."
Supports routine autism evaluation regardless of reported diagnosis.
🩻

Imaging Findings

2
Reduced Cerebellar Cortex Volume
Quantitative structural MRI shows smaller cerebellar cortex volume with an anterior-posterior gradient, and larger cerebellar white matter volume, relative to neurotypical controls.
Mri
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON)
Show evidence (1 reference)
PMID:38744992 SUPPORT Human Clinical
"An anterior-posterior gradient emerged in finer grained lobule-based and voxel-wise analyses."
Documents the spatial gradient of the volumetric deficit.
Posterior Fossa Cystic Malformation
Arachnoid cysts and mega cisterna magna occur at elevated rates and independent of cerebellar volume. Worth recording precisely because they are the finding most likely to be reported as an incidental note — and, unlike the volumetric measures, they carry no demonstrated behavioural association.
Mri
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON)
Show evidence (1 reference)
PMID:38744992 SUPPORT Human Clinical
"Cerebellar white matter and subregional gray matter volumes were associated with visual-perception and visual-motor integration skills as well as IQ, while cystic/cyst-like malformations yielded no behavioral link."
Establishes that the cystic findings, unlike the volumetrics, do not predict function.
📊

Prevalence

1
Worldwide
Point Prevalence 3.3 per 100,000 1–9 per 100,000
Approximately 1 in 30,000, converted arithmetically to a rate per 100,000.
Show evidence (2 references)
PMID:38744992 SUPPORT Human Clinical
"3q29Del has a prevalence of ~1 in 30,000 and usually arises de novo due to the hemizygous deletion of a 1.6-Mb locus, spanning 21 protein-coding genes"
Source of both the prevalence estimate and the de novo characterization.
PMID:32321479 SUPPORT Human Clinical
"The presence of these unaffected or mildly affected individuals suggests there may be an ascertainment bias for severely affected cases of 3q29 deletion syndrome, thus the more deleterious consequence of the 3q29 deletion may be overestimated."
An important caveat on every frequency in this entry: cohorts are assembled from ascertained probands, so mildly affected carriers are systematically under-counted and the severity figures here should be read as upper bounds.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Chromosome 3q29 Microdeletion Syndrome:

3q29 microduplication syndrome
Overlapping Features The reciprocal product of the same non-allelic homologous recombination event at the same locus. It shares the mechanism and the interval but is a distinct, generally milder disorder — a useful natural dosage comparator rather than a diagnostic trap, since microarray distinguishes them unambiguously.
Distinguishing Features
  • Copy-number gain rather than loss at the same interval
  • Generally milder and more variable phenotype
Show evidence (1 reference)
PMID:32874693 SUPPORT Human Clinical
"3q29 microduplication syndrome is characterized by widely variable clinical presentation, but generally mild features."
Characterizes the reciprocal disorder as milder and more variable, which is the distinction this entry draws.
22q11.2 deletion syndrome
Overlapping Features The other recurrent CNV strongly associated with schizophrenia, and the one this syndrome is most often compared with mechanistically — mitochondrial phenotypes have been reported for both, raising the possibility of convergent biology downstream of distinct CNVs.
Distinguishing Features
  • Different locus, resolved by microarray
  • Conotruncal cardiac defects, hypoparathyroidism and immunodeficiency are characteristic of 22q11.2 and not of this syndrome
🧫

Experimental Models

1
Isogenic 3q29 deletion human cortical organoids ORGANOID
Human cortical organoids carrying the full 1.6 Mb deletion introduced by CRISPR-Cas9 into a neurotypical iPSC background, profiled by single-cell RNA sequencing at 2 and 12 months. The isogenic design is what makes them informative: it removes the genetic-background variability that otherwise confounds patient-derived comparisons for a variably expressive CNV.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
CRISPR-engineered isogenic induced pluripotent stem cell lines
Publication
PMID:37585521
Pathograph links
Mitochondrial and Energy-Metabolism Dysregulation recapitulates fidelity: moderate The human half of the cross-species convergence on mitochondrial function and energy metabolism in developing cortical tissue.
Limitations: Organoids model early cortical development and lack vasculature, microglia and mature circuit activity, so they cannot address the adolescent-to-adult window in which psychosis emerges — the phenotype the finding is ultimately being used to explain.
Show evidence (1 reference)
PMID:37585521 SUPPORT In Vitro
"We interrogated the developing neural transcriptome in two experimental model systems with complementary advantages: isogenic human cortical organoids and isocortex from the 3q29Del mouse model."
Identifies the organoid system and its role in the cross-species design.
🐁

Animal Models

3
3q29 deletion (Df/+) mouse
A chromosome-engineered mouse carrying the syntenic deletion, offering construct validity by design and, as it turned out, elements of face and predictive validity too.
Species
Mouse
Genotype
Chromosome-engineered deletion syntenic to the human 3q29 interval
Publication
PMID:31216562
Pathograph links
Cortical Excitation-Inhibition Imbalance recapitulates fidelity: moderate Regionally restricted cortical neuronal hyperactivation with reduced parvalbumin expression, plus impaired prepulse inhibition that is reversed by antipsychotics.
Limitations: Prepulse inhibition is a sensorimotor gating proxy, not psychosis; a mouse cannot model the syndrome's defining psychiatric outcome, and its reversal by antipsychotics demonstrates pharmacological responsiveness of the proxy rather than of the human illness. Reduced parvalbumin expression is a marker measurement, not a demonstration of interneuron loss.
Show evidence (1 reference)
PMID:31216562 SUPPORT Model Organism
"Importantly, the schizophrenia-related impaired prepulse inhibition was reversed by administration of antipsychotics."
The predictive-validity observation, recorded together with its limitation.
Show evidence (1 reference)
PMID:31216562 SUPPORT Model Organism
"3q29 deletion (Df/+) mice showed reduced body weight and brain volume and, more importantly, impaired social interaction and prepulse inhibition."
Establishes the model's phenotypic repertoire, including the growth and brain volume correlates of the human syndrome.
CRISPR-engineered 3q29 deletion mouse
An independently generated model of the same deletion, used as the in vivo arm of the cross-species transcriptomic analysis.
Species
Mouse
Genotype
B6.Del16+/Bdh1-Tfrc, CRISPR-engineered syntenic 3q29 deletion
Publication
PMID:30976085
Pathograph links
Mitochondrial and Energy-Metabolism Dysregulation recapitulates fidelity: moderate Perinatal isocortex from this model contributed the mouse half of the cross-species convergence on mitochondrial and energy-metabolism pathways.
Limitations: The convergent signature was derived at a single perinatal timepoint in mouse and at two timepoints in organoids; neither addresses adult cortex, and the metabolic deficit has not been measured in tissue from affected individuals.
Show evidence (1 reference)
PMID:37585521 SUPPORT Model Organism
"We profiled transcriptomes from isogenic cortical organoids that were aged for 2 and 12 months, as well as perinatal mouse isocortex, all at single-cell resolution."
Identifies the mouse tissue and timepoint contributing to the convergence.
Drosophila and Xenopus 3q29 homolog knockdown panel
Not a model of the deletion but a dissection of it: a 314-combination pairwise knockdown screen designed to ask which genes in the interval interact, which is the question a syntenic deletion model cannot answer.
Species
Drosophila melanogaster and Xenopus laevis
Genotype
Tissue-specific individual and pairwise knockdown of 14 homologs of 3q29 genes
Publication
PMID:32053595
Pathograph links
Combinatorial Haploinsufficiency Across the 3q29 Interval perturbs fidelity: low Systematic pairwise perturbation identified 44 interactions between 3q29 gene homolog pairs and 34 with other neurodevelopmental genes, with NCBP2 emerging as a broad enhancer acting through apoptosis.
Limitations: Invertebrate and amphibian homolog knockdown is a screen for interaction structure, not a model of human haploinsufficiency; knockdown is not hemizygosity, and the eye and brain readouts are not the human phenotypes. The finding earns its place because it answers a combinatorial question no mammalian deletion model addresses, not because it recapitulates the disease.
Show evidence (1 reference)
PMID:32053595 SUPPORT Model Organism
"Using the fly eye, we screened for 314 pairwise knockdowns of homologs of 3q29 genes and identified 44 interactions between pairs of homologs and 34 interactions with other neurodevelopmental genes."
The scale and result of the interaction screen.
{ }

Source YAML

click to show 
name: Chromosome 3q29 Microdeletion Syndrome
creation_date: "2026-08-15T00:00:00Z"
category: Genetic
parents:
- Chromosomal deletion syndrome
- Neurodevelopmental disorder
synonyms:
- 3q29 deletion syndrome
- 3q29 microdeletion syndrome
- 3q29 recurrent deletion
- 3q subtelomere deletion syndrome
- 3qter deletion
disease_term:
  preferred_term: Chromosome 3q29 Microdeletion Syndrome
  term:
    id: MONDO:0012269
    label: chromosome 3q29 microdeletion syndrome
description: >-
  3q29 deletion syndrome is a recurrent ~1.6 Mb subtelomeric copy-number disorder,
  generated by non-allelic homologous recombination between the low-copy repeats
  that flank the interval and usually arising de novo. Hemizygous loss of the ~21
  protein-coding genes inside it produces a broad neurodevelopmental and
  neuropsychiatric phenotype — mild-to-moderate intellectual disability, autism
  spectrum disorder, ADHD, anxiety, executive-function and graphomotor deficits —
  together with a systemic burden that is easy to underweight: gastrointestinal
  symptoms are actually the commonest manifestation, and congenital heart defects
  the most severe.

  Two things make this entry worth curating carefully rather than filing as
  "another recurrent CNV". First, the schizophrenia risk is exceptional. The
  deletion carries at least a 40-fold increase in risk, one of the largest effect
  sizes known anywhere in the genetics of schizophrenia, and psychosis can begin
  earlier than in the general population. Second, no single gene in the interval
  has been shown to be necessary and sufficient. Single-gene knockouts of the
  leading candidates do not reproduce the syndrome; what the functional work
  supports instead is combinatorial haploinsufficiency, with NCBP2 acting as a
  broad enhancer of the other genes' phenotypes and PAK2 contributing to a
  mitochondrial-metabolic deficit conserved from human organoids to mouse cortex.
  The entry models that as a genuine multi-gene node rather than nominating a
  driver the evidence does not support.
inheritance:
- name: Autosomal dominant, typically de novo
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    The deletion is dominant in transmission but usually arises de novo, so most
    probands are simplex. Sibling recurrence risk is low but not zero because of
    possible parental mosaicism; an affected individual transmits the deletion to
    half their offspring.
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29 recurrent deletion is an autosomal dominant disorder typically caused by
      a de novo deletion.
    explanation: >-
      GeneReviews states the mode of inheritance and its usual de novo origin.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the proband represents a simplex case (i.e., a single affected family
      member) and neither parent has the 3q29 recurrent deletion or a balanced
      chromosome rearrangement, the recurrence risk to sibs is low (presumed to be
      <1%) but greater than that of the general population because of the
      possibility of parental mosaicism for the deletion.
    explanation: >-
      Source of the recurrence-risk statement, including the mosaicism caveat.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.3
  notes: >-
    Approximately 1 in 30,000, converted arithmetically to a rate per 100,000.
  evidence:
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29Del has a prevalence of ~1 in 30,000 and usually arises de novo due to the
      hemizygous deletion of a 1.6-Mb locus, spanning 21 protein-coding genes
    explanation: >-
      Source of both the prevalence estimate and the de novo characterization.
  - reference: PMID:32321479
    reference_title: >-
      Comprehensive phenotyping of neuropsychiatric traits in a multiplex 3q29
      deletion family: a case report.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of these unaffected or mildly affected individuals suggests there
      may be an ascertainment bias for severely affected cases of 3q29 deletion
      syndrome, thus the more deleterious consequence of the 3q29 deletion may be
      overestimated.
    explanation: >-
      An important caveat on every frequency in this entry: cohorts are assembled
      from ascertained probands, so mildly affected carriers are systematically
      under-counted and the severity figures here should be read as upper bounds.
pathophysiology:
- name: Non-Allelic Homologous Recombination at 3q29 Low-Copy Repeats
  biological_scale: MOLECULAR
  description: >-
    The initiating event, and the reason the deletion is recurrent rather than
    private. Two nearly identical low-copy repeats flank the interval; misalignment
    between them during meiosis and unequal crossing-over excises the intervening
    sequence, producing near-identical breakpoints in unrelated patients. The
    reciprocal product of the same event is the 3q29 microduplication, which is a
    distinct and generally milder disorder.
  biological_processes:
  - preferred_term: recombinational repair
    term:
      id: GO:0000725
      label: recombinational repair
    modifier: ABNORMAL
  downstream:
  - target: Combinatorial Haploinsufficiency Across the 3q29 Interval
    causal_link_type: DIRECT
    description: >-
      The excision leaves one functional copy of every gene in the interval.
  evidence:
  - reference: PMID:15918153
    reference_title: >-
      3q29 microdeletion syndrome: clinical and molecular characterization of a new
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of two nearly identical low-copy repeat sequences in BAC clones
      on each side of the deletion breakpoint suggests that nonallelic homologous
      recombination is the likely mechanism of disease causation in this syndrome.
    explanation: >-
      Original identification of the recombination mechanism.
  - reference: PMID:15918153
    reference_title: >-
      3q29 microdeletion syndrome: clinical and molecular characterization of a new
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The microdeletion is approximately 1.5 Mb in length, with molecular boundaries
      mapping within the same or adjacent bacterial artificial chromosome (BAC)
      clones at either end of the deletion in all patients.
    explanation: >-
      Documents the near-identical breakpoints that make the deletion recurrent.
- name: Combinatorial Haploinsufficiency Across the 3q29 Interval
  biological_scale: MOLECULAR
  description: >-
    Hemizygosity for the ~21 protein-coding genes in the interval. The
    load-bearing curatorial point is negative: no single gene has been shown to be
    necessary and sufficient for the syndrome, and this node deliberately does not
    nominate one. The leading candidates are DLG1 and PAK2, autosomal paralogues of
    the X-linked intellectual disability genes DLG3 and PAK3, and NCBP2, which
    behaves as a broad enhancer of the other genes' phenotypes rather than as a
    driver in its own right. A pairwise interaction screen across 314 combinations
    of 14 homologs found dozens of interactions and traced the NCBP2 effect to
    increased apoptosis, which was rescued by apoptosis inhibitors — evidence that
    the mechanism is interaction between genes in the interval, not the failure of
    any one of them.
  genes:
  - preferred_term: DLG1
    term:
      id: hgnc:2900
      label: DLG1
  - preferred_term: PAK2
    term:
      id: hgnc:8591
      label: PAK2
  - preferred_term: NCBP2
    term:
      id: hgnc:7659
      label: NCBP2
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
  downstream:
  - target: Mitochondrial and Energy-Metabolism Dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced dosage across the interval, with a demonstrated PAK2 contribution,
      converges on mitochondrial function and metabolic flexibility.
  - target: Cortical Excitation-Inhibition Imbalance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced gene dosage produces cortical hyperactivity and reduced
      parvalbumin-interneuron marker expression in the mouse model; the steps
      between are not established.
  - target: Posterior Fossa and Cerebellar Maldevelopment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The cerebellum and posterior fossa are disproportionately affected, but no
      specific gene in the interval has been tied to that regional vulnerability.
  evidence:
  - reference: PMID:15918153
    reference_title: >-
      3q29 microdeletion syndrome: clinical and molecular characterization of a new
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The deletion encompasses 22 genes, including PAK2 and DLG1, which are
      autosomal homologues of two known X-linked mental retardation genes, PAK3 and
      DLG3.
    explanation: >-
      Identifies the two original candidate genes and the paralogy argument for
      them.
  - reference: PMID:32053595
    reference_title: >-
      NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila
      and Xenopus laevis models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Interestingly, NCBP2 homologs in Drosophila (Cbp20) and X. laevis (ncbp2)
      enhanced the phenotypes of homologs of the other 3q29 genes, leading to
      significant increases in apoptosis that disrupted cellular organization and
      brain morphology.
    explanation: >-
      The enhancer role of NCBP2 and its apoptotic readout, which is why this node
      is combinatorial rather than single-gene.
  - reference: PMID:32053595
    reference_title: >-
      NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila
      and Xenopus laevis models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Overall, our study suggests that NCBP2-mediated genetic interactions within
      the 3q29 region disrupt apoptosis and cell cycle mechanisms during
      development.
    explanation: >-
      States the interaction-based mechanism this node encodes.
  - reference: PMID:34131099
    reference_title: >-
      Convergent and distributed effects of the 3q29 deletion on the human neural
      transcriptome.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      The 21 protein-coding genes located in the interval segregated into seven
      clusters of highly co-expressed genes, demonstrating both convergent and
      distributed effects of 3q29Del across the interrogated transcriptomic
      landscape.
    explanation: >-
      Human cortical network analysis showing the interval's genes are neither one
      functional unit nor 21 unrelated ones, which is what "combinatorial" means
      here.
  - reference: PMID:34131099
    reference_title: >-
      Convergent and distributed effects of the 3q29 deletion on the human neural
      transcriptome.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      However, no single gene in this interval is definitively associated with
      disease, prompting the hypothesis that neuropsychiatric sequelae emerge upon
      loss of multiple functionally-connected genes.
    explanation: >-
      States the multi-gene hypothesis this node is built on.
- name: Mitochondrial and Energy-Metabolism Dysregulation
  biological_scale: CELLULAR
  description: >-
    The best-supported molecular consequence, and notable for how it was
    established: single-cell transcriptomes from isogenic human cortical organoids
    and from mouse isocortex converged independently on mitochondrial function and
    energy metabolism, and the signature was then confirmed at the level of
    oxidative-phosphorylation complex protein expression and functional assays. The
    functional deficit is described as a lack of metabolic flexibility rather than a
    flat loss of respiratory capacity, and PAK2 is identified as a contributor. The
    cross-species convergence is what raises this above a single transcriptomic
    observation.
  genes:
  - preferred_term: PAK2
    term:
      id: hgnc:8591
      label: PAK2
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DYSREGULATED
  cell_types:
  - preferred_term: glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  downstream:
  - target: Neurodevelopmental and Neuropsychiatric Phenotype
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Metabolic constraint on developing cortical neurons is proposed to contribute
      to the neurodevelopmental outcome; the connecting steps are not established.
  evidence:
  - reference: PMID:37585521
    reference_title: >-
      Cross-species analysis identifies mitochondrial dysregulation as a functional
      consequence of the schizophrenia-associated 3q29 deletion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Systematic pathway analysis implicated dysregulation of mitochondrial function
      and energy metabolism.
    explanation: >-
      The transcriptomic finding in isogenic organoids and mouse isocortex.
  - reference: PMID:37585521
    reference_title: >-
      Cross-species analysis identifies mitochondrial dysregulation as a functional
      consequence of the schizophrenia-associated 3q29 deletion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These molecular signatures were supported by analysis of oxidative
      phosphorylation protein complex expression in mouse brain and assays of
      mitochondrial function in engineered cell lines, which revealed a lack of
      metabolic flexibility and a contribution of the 3q29 gene PAK2.
    explanation: >-
      Orthogonal protein-level and functional confirmation, and the PAK2
      attribution.
- name: Cortical Excitation-Inhibition Imbalance
  biological_scale: TISSUE
  description: >-
    In the syntenic mouse model, whole-brain imaging after a behavioural task showed
    neuronal hyperactivation that was strikingly exaggerated but spatially
    restricted rather than global, accompanied by reduced parvalbumin expression in
    cortex. That combination — excess excitatory activity with reduced inhibitory
    interneuron marker expression — is the standard shape of an excitation-inhibition
    imbalance, and it is the cellular phenotype the mouse work offers for the
    psychiatric arm of the syndrome. It is a model-organism finding; no equivalent
    human cortical measurement exists.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DYSREGULATED
  locations:
  - preferred_term: neocortex
    term:
      id: UBERON:0001950
      label: neocortex
  mechanism_confidence: PROVISIONAL
  downstream:
  - target: Neurodevelopmental and Neuropsychiatric Phenotype
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Cortical circuit imbalance is the proposed substrate for the psychiatric
      phenotype, on the strength of model-organism evidence only.
  evidence:
  - reference: PMID:31216562
    reference_title: >-
      Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity
      in a mouse model of 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We further elucidated the cellular phenotypes of neuronal hyperactivation and
      the reduction of parvalbumin expression in the cortex of Df/+ mice.
    explanation: >-
      The two cellular measurements that constitute this node.
  - reference: PMID:31216562
    reference_title: >-
      Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity
      in a mouse model of 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Unbiased whole-brain imaging revealed that neuronal hyperactivation after a
      behavioral task was strikingly exaggerated in a restricted region of the
      cortex of Df/+ mice.
    explanation: >-
      Establishes that the hyperactivation is regionally restricted rather than
      global.
- name: Posterior Fossa and Cerebellar Maldevelopment
  biological_scale: TISSUE
  description: >-
    A structural signature specific enough to be a candidate biomarker. Quantitative
    MRI shows smaller cerebellar cortex volumes and, in the opposite direction,
    larger cerebellar white matter volumes, together with elevated rates of
    posterior fossa arachnoid cysts and mega cisterna magna. The dissociation within
    that list matters: cerebellar grey and white matter volumes track visual
    perception, visual-motor integration and IQ, whereas the cystic malformations —
    the findings most likely to be flagged on a clinical read — showed no behavioural
    association at all. Reporting the cyst without the volumetrics would therefore be
    reporting the part that does not predict anything.
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29Del participants had smaller cerebellar cortex volumes than controls,
      before and after correction for intracranial volume (ICV).
    explanation: >-
      The primary volumetric finding.
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29Del participants also had larger cerebellar white matter volumes than
      controls following ICV-correction and displayed elevated rates of posterior
      fossa arachnoid cysts and mega cisterna magna findings independent of
      cerebellar volume.
    explanation: >-
      The white-matter and cystic findings, and their independence from cerebellar
      volume.
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cerebellar white matter and subregional gray matter volumes were associated
      with visual-perception and visual-motor integration skills as well as IQ,
      while cystic/cyst-like malformations yielded no behavioral link.
    explanation: >-
      The dissociation between the volumetric findings, which predict function, and
      the cystic findings, which do not.
- name: Neurodevelopmental and Neuropsychiatric Phenotype
  biological_scale: ORGANISM
  description: >-
    The clinical output. Neurodevelopmental burden dominates — intellectual
    disability, autism spectrum disorder, executive-function deficits and graphomotor
    weakness — and psychiatric illness accumulates across the lifespan, with anxiety
    and ADHD common in childhood and psychosis emerging later, at an age that can
    precede the usual population onset. The cognitive profile has a specific shape
    rather than being uniformly depressed: verbal ability typically exceeds
    non-verbal, which can mask the non-verbal deficit and lead to overestimation of
    overall ability.
  cell_types:
  - preferred_term: glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental phenotypes represent a significant burden and include
      intellectual disability (34%), autism spectrum disorder (38%), executive
      function deficits (46%), and graphomotor weakness (78%).
    explanation: >-
      Quantifies the neurodevelopmental component from a systematic phenotyping
      protocol.
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Psychiatric illness manifests across the lifespan with psychosis prodrome
      (15%), psychosis (20%), anxiety disorders (40%), and attention
      deficit-hyperactivity disorder (ADHD) (63%).
    explanation: >-
      Quantifies the psychiatric component across the lifespan.
  - reference: PMID:35297118
    reference_title: A distinct cognitive profile in individuals with 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two-thirds of individuals with the deletion will exhibit significant strength
      in verbal ability; this may mask deficits in non-verbal reasoning, leading to
      an overestimation of overall ability.
    explanation: >-
      Establishes the verbal-over-non-verbal profile and its clinical consequence.
phenotypes:
- category: Neurologic
  name: Global Developmental Delay
  description: >-
    Developmental delay is usually what brings a child with this deletion to genetic
    testing, and the deep-research report puts it at 70-90%. No frequency band is
    asserted, because that figure is not quotable from any reference cited here: the
    GeneReviews abstract names developmental delay only through "speech delays", and
    the deep-phenotyping cohort reports intellectual disability, autism,
    executive-function and graphomotor figures without a separate delay rate. Banding
    it would mean asserting a number this entry cannot show, and the 70-90% range
    straddles the FREQUENT/VERY_FREQUENT boundary in any case. The qualitative
    association is well supported and is what the evidence below carries.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: DOI:10.3389/frcha.2026.1823061
    reference_title: >-
      Case Report: Early-onset psychosis as a sentinel manifestation of 3q29 deletion
      syndrome in an adolescent with neurodevelopmental disorders
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29 deletion syndrome is a rare genomic disorder characterized by a broad
      spectrum of neurodevelopmental and psychiatric manifestations, including
      developmental delay (DD), intellectual disability (ID), autism spectrum
      disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and a markedly
      increased lifetime risk of psychosis and schizophrenia.
    explanation: >-
      Names developmental delay explicitly as a characteristic manifestation. Supports
      the association, not a rate.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29 recurrent deletion is characterized by neurodevelopmental and/or
      psychiatric manifestations including mild-to-moderate intellectual disability
      (ID), autism spectrum disorder (ASD), anxiety disorders,
      attention-deficit/hyperactivity disorder (ADHD), executive function deficits,
      graphomotor weakness, and psychosis/schizophrenia.
    explanation: >-
      GeneReviews frames the disorder as defined by its neurodevelopmental
      manifestations. PARTIAL because the list names intellectual disability and the
      specific cognitive deficits rather than global developmental delay as such.
- category: Neurologic
  name: Executive Function Deficits
  frequency: FREQUENT
  description: >-
    Clinically significant executive-function deficits affect roughly half of
    individuals, and they matter independently of IQ: they relate to functional,
    clinical and neuroimaging outcomes rather than simply tracking general ability.
    No HPO term is bound because the closest candidate (HP:0031466, impairment in
    personality function) does not mean this; per the no-term-beats-a-bad-one rule
    the entry is curated with a descriptive name and left unbound.
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental phenotypes represent a significant burden and include
      intellectual disability (34%), autism spectrum disorder (38%), executive
      function deficits (46%), and graphomotor weakness (78%).
    explanation: >-
      Gives the 46% figure underlying the FREQUENT band.
  - reference: PMID:39365000
    reference_title: >-
      Beyond IQ: executive function deficits and their relation to functional,
      clinical, and neuroimaging outcomes in 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prior work by our team identified clinically significant executive function
      (EF) deficits in 47% of individuals with 3q29del; however, the nuances of EF in
      this population have not been described.
    explanation: >-
      Independent confirmation of the rate, from the study dedicated to the domain.
- category: Neurologic
  name: Graphomotor Weakness
  frequency: FREQUENT
  description: >-
    Graphomotor weakness is the single most frequent neurodevelopmental finding on
    systematic evaluation, present in about four-fifths of individuals — more common
    than intellectual disability or autism, and more likely to be missed. Left
    unbound: HPO has no term for graphomotor weakness that is not a broader
    fine-motor or writing-ability concept.
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental phenotypes represent a significant burden and include
      intellectual disability (34%), autism spectrum disorder (38%), executive
      function deficits (46%), and graphomotor weakness (78%).
    explanation: >-
      Gives the 78% figure underlying the FREQUENT band.
- category: Ophthalmologic
  name: Ocular Involvement
  frequency: FREQUENT
  description: >-
    Ophthalmologic involvement affects a majority of individuals — 59% in the
    deep-phenotyping cohort — with strabismus the commonest specific finding at 28%.
    GeneReviews prescribes annual ophthalmology examination on the strength of it.
    The percentages are given here rather than quoted because the sentences carrying
    them use thin-space characters inside their sample-size parentheticals, which
    would make the snippets fragile; the quoted spans below avoid those.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ocular issues, dental anomalies, and congenital heart defects (especially
      patent ductus arteriosus).
    explanation: >-
      GeneReviews names ocular issues among the common findings.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      routine management of musculoskeletal issues, GERD, strabismus, dental issues,
      congenital heart defects, recurrent ear infections, and epistaxis
    explanation: >-
      Identifies strabismus specifically as a managed manifestation.
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      had a symptom or diagnosis related to the eye. The most common ocular phenotype
      was strabismus
    explanation: >-
      Systematic-cohort confirmation that ocular involvement is common and that
      strabismus is its commonest form.
- category: Craniofacial
  name: Dental Anomalies
  frequency: FREQUENT
  description: >-
    Dental anomalies affect roughly 40% of individuals and are enough of a burden that
    GeneReviews prescribes six-monthly dental examination. The cohort figure is 41%,
    commonly enamel hypoplasia with caries proclivity and abnormalities of tooth
    number and size.
  phenotype_term:
    preferred_term: Abnormality of the dentition
    term:
      id: HP:0000164
      label: Abnormality of the dentition
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ocular issues, dental anomalies, and congenital heart defects (especially
      patent ductus arteriosus).
    explanation: >-
      GeneReviews names dental anomalies among the common findings.
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dental anomalies were reported in 41%
    explanation: >-
      Gives the cohort figure underlying the FREQUENT band.
- category: Otologic
  name: Recurrent Otitis Media
  frequency: OCCASIONAL
  description: >-
    Recurrent ear infections affect roughly a fifth of individuals and are named among
    the manifestations requiring routine management.
  phenotype_term:
    preferred_term: Otitis media
    term:
      id: HP:0000388
      label: Otitis media
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      routine management of musculoskeletal issues, GERD, strabismus, dental issues,
      congenital heart defects, recurrent ear infections, and epistaxis
    explanation: >-
      Names recurrent ear infections among the manifestations requiring routine
      management.
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      had recurrent ear infections, and three subjects required surgery.
    explanation: >-
      Systematic-cohort confirmation, including that a subset required surgical
      management.
- category: Neurologic
  name: Intellectual Disability
  frequency: FREQUENT
  description: >-
    Mild-to-moderate intellectual disability, formally diagnosed in about a third of
    systematically evaluated individuals. Mean full-scale IQ is 73 with a wide range,
    so the group spans normal-range ability to moderate impairment.
  phenotype_term:
    preferred_term: Mild intellectual disability
    term:
      id: HP:0001256
      label: Mild intellectual disability
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental phenotypes represent a significant burden and include
      intellectual disability (34%), autism spectrum disorder (38%), executive
      function deficits (46%), and graphomotor weakness (78%).
    explanation: >-
      Gives the 34% figure underlying the FREQUENT band.
  - reference: PMID:35297118
    reference_title: A distinct cognitive profile in individuals with 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mean full scale IQ was 73 (range 40-99).
    explanation: >-
      Quantifies the cognitive range in a standardized-protocol cohort.
- category: Neurologic
  name: Autism Spectrum Disorder
  frequency: FREQUENT
  description: >-
    Autism spectrum disorder is diagnosed in roughly a third of affected individuals
    — around a twenty-fold enrichment over the general population — and the
    phenotype is qualitatively distinctive rather than simply more common: restricted
    interests and repetitive behaviours are substantially elevated while social
    motivation is only mildly impaired, the inverse of the usual idiopathic profile.
    The male bias is also attenuated, from about 4:1 in the general population to 2:1
    here.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:31346402
    reference_title: >-
      Neuropsychiatric phenotypes and a distinct constellation of ASD features in
      3q29 deletion syndrome: results from the 3q29 registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29Del cases report a higher prevalence of autism diagnoses versus the
      general population (29.0% vs. 1.47%, p < 2.2E- 16).
    explanation: >-
      Quantifies both the rate and the enrichment over population baseline.
  - reference: PMID:31346402
    reference_title: >-
      Neuropsychiatric phenotypes and a distinct constellation of ASD features in
      3q29 deletion syndrome: results from the 3q29 registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Finally, cases show a distinct constellation of ASD features on the SRS as
      compared to idiopathic ASD, with substantially elevated Restricted Interests
      and Repetitive Behaviors, but only mild impairment in Social Motivation.
    explanation: >-
      Establishes the qualitative distinctiveness of the autism phenotype here.
  - reference: PMID:31346402
    reference_title: >-
      Neuropsychiatric phenotypes and a distinct constellation of ASD features in
      3q29 deletion syndrome: results from the 3q29 registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, 3q29 deletion confers a greater influence on risk for ASD in females
      (OR = 41.8, p = 4.78E- 05) than in males (OR = 24.6, p = 6.06E- 09); this is
      aligned with the reduced male:female bias from 4:1 in the general population
      to 2:1 in our study sample.
    explanation: >-
      Documents the attenuated male bias and the sex-differential effect size.
- category: Psychiatric
  name: Psychosis and Schizophrenia
  frequency: OCCASIONAL
  diagnostic: true
  description: >-
    Psychosis occurs in about a fifth of affected individuals, with a further ~15%
    showing prodromal features. In relative terms this is the headline finding of the
    disorder — at least a 40-fold increase in risk, among the largest effect sizes
    known in schizophrenia genetics — even though in absolute terms most carriers do
    not develop psychosis. Onset can be earlier than the usual population onset,
    which is what makes the surveillance recommendation actionable rather than
    routine.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Psychiatric illness manifests across the lifespan with psychosis prodrome
      (15%), psychosis (20%), anxiety disorders (40%), and attention
      deficit-hyperactivity disorder (ADHD) (63%).
    explanation: >-
      Gives the 20% psychosis figure underlying the OCCASIONAL band.
  - reference: PMID:37585521
    reference_title: >-
      Cross-species analysis identifies mitochondrial dysregulation as a functional
      consequence of the schizophrenia-associated 3q29 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hemizygous loss of this set of genes is associated with at least a 40-fold
      increase in risk for SCZ
    explanation: >-
      Secondary statement of the relative risk, in the paper that established the
      mitochondrial mechanism.
  - reference: PMID:26055425
    reference_title: >-
      The 3q29 deletion confers >40-fold increase in risk for schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results of this analysis indicate that the 3q29 deletion confers a
      41.1-fold increased risk for SZ
    explanation: >-
      The primary meta-analytic source for the effect size, cited alongside the
      secondary statement rather than in place of it.
  - reference: PMID:26055425
    reference_title: >-
      The 3q29 deletion confers >40-fold increase in risk for schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The range of OR estimates (33.3-41.1) suggests that larger samples may be
      exerting upward influence on the estimate of risk, but no one sample is driving
      the observed effect size.
    explanation: >-
      Records the authors' own uncertainty range, which the round "40-fold" figure
      conceals.
  - reference: PMID:20691406
    reference_title: Microdeletions of 3q29 confer high risk for schizophrenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified six 3q29 deletions among 7545 schizophrenic subjects and one
      among 39,748 controls, resulting in a statistically significant association
      with SZ (p = 0.02) and an odds ratio estimate of 17 (95% confidence interval:
      1.36-1198.4)
    explanation: >-
      The original association report. PARTIAL because its point estimate of 17 and
      enormous confidence interval have been superseded by the later meta-analysis;
      quoted to show how the estimate was originally bounded.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Age at onset for psychosis or prodrome can be younger than the typical age at
      onset in the general population.
    explanation: >-
      Supports the earlier-onset statement driving psychiatric surveillance.
  - reference: DOI:10.3389/frcha.2026.1823061
    reference_title: >-
      Case Report: Early-onset psychosis as a sentinel manifestation of 3q29 deletion
      syndrome in an adolescent with neurodevelopmental disorders
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29 deletion syndrome is a rare genomic disorder characterized by a broad
      spectrum of neurodevelopmental and psychiatric manifestations, including
      developmental delay (DD), intellectual disability (ID), autism spectrum
      disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and a markedly
      increased lifetime risk of psychosis and schizophrenia.
    explanation: >-
      A single case in which early-onset psychosis was the sentinel manifestation.
      PARTIAL because one case cannot establish a rate, only that the presentation
      occurs.
- category: Psychiatric
  name: Attention Deficit Hyperactivity Disorder
  frequency: FREQUENT
  description: >-
    The single commonest psychiatric diagnosis in systematically evaluated cohorts,
    present in roughly two-thirds.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Psychiatric illness manifests across the lifespan with psychosis prodrome
      (15%), psychosis (20%), anxiety disorders (40%), and attention
      deficit-hyperactivity disorder (ADHD) (63%).
    explanation: >-
      Gives the 63% ADHD figure underlying the FREQUENT band.
- category: Psychiatric
  name: Anxiety Disorder
  frequency: FREQUENT
  description: >-
    Anxiety disorders affect roughly 40% on systematic evaluation, and generalized
    anxiety disorder is several-fold more frequent than in controls on registry
    self-report.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Psychiatric illness manifests across the lifespan with psychosis prodrome
      (15%), psychosis (20%), anxiety disorders (40%), and attention
      deficit-hyperactivity disorder (ADHD) (63%).
    explanation: >-
      Gives the 40% anxiety figure underlying the FREQUENT band.
  - reference: PMID:31346402
    reference_title: >-
      Neuropsychiatric phenotypes and a distinct constellation of ASD features in
      3q29 deletion syndrome: results from the 3q29 registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cases also report increased frequency of generalized anxiety disorder compared
      to controls (28.0% vs. 6.2%, p = 0.001)
    explanation: >-
      Independent case-control confirmation from the registry cohort.
  - reference: PMID:38216835
    reference_title: >-
      Behavioral Phenotypes and Comorbidity in 3q29 Deletion Syndrome: Results from
      the 3q29 Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with 3q29del showed significantly elevated behavioral and
      developmental impairment relative to controls across CBCL/ABCL domains.
    explanation: >-
      Instrument-based confirmation of elevated behavioural burden against a control
      group.
- category: Neurologic
  name: Delayed Speech and Language Development
  frequency: FREQUENT
  description: >-
    Speech delay is common and is the target of the earliest recommended
    intervention. It also has prognostic weight: age at first two-word phrases is
    strongly associated with later verbal ability.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early speech and language therapy to address speech delays; physical/occupational
      therapy as needed to address motor issues
    explanation: >-
      GeneReviews management guidance presupposes speech delay as a standard feature.
  - reference: PMID:35297118
    reference_title: A distinct cognitive profile in individuals with 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at which a child first spoke two-word phrases was strongly associated
      with measures of verbal ability (P value 2.56e-07).
    explanation: >-
      Supports the prognostic significance of the speech delay.
- category: Gastrointestinal
  name: Gastrointestinal Symptoms
  frequency: VERY_FREQUENT
  description: >-
    The commonest manifestation of the syndrome by organ system, present in about
    four-fifths of individuals — a point easily lost behind the neuropsychiatric
    findings. Includes feeding difficulty in infancy, gastroesophageal reflux and
    constipation.
  phenotype_term:
    preferred_term: Abnormality of the gastrointestinal tract
    term:
      id: HP:0011024
      label: Abnormality of the gastrointestinal tract
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most severe manifestations were congenital heart defects (25%) and the
      most common were gastrointestinal symptoms (81%).
    explanation: >-
      Gives the 81% figure and the explicit statement that GI symptoms are the
      commonest manifestation. The term is bound at the umbrella level because 81%
      is the rate for gastrointestinal symptoms as a class, not for any single one.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are failure to thrive and feeding problems in infancy
      that persist into childhood, gastrointestinal disorders (including
      constipation and gastroesophageal reflux disease [GERD])
    explanation: >-
      Enumerates the specific gastrointestinal manifestations.
- category: Gastrointestinal
  name: Gastroesophageal Reflux
  frequency: FREQUENT
  description: Gastroesophageal reflux disease, part of the dominant gastrointestinal burden.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are failure to thrive and feeding problems in infancy
      that persist into childhood, gastrointestinal disorders (including
      constipation and gastroesophageal reflux disease
    explanation: >-
      GeneReviews names GERD among the common gastrointestinal findings.
- category: Gastrointestinal
  name: Constipation
  frequency: FREQUENT
  description: Chronic constipation, part of the dominant gastrointestinal burden.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are failure to thrive and feeding problems in infancy
      that persist into childhood, gastrointestinal disorders (including
      constipation and gastroesophageal reflux disease
    explanation: >-
      GeneReviews names constipation among the common gastrointestinal findings.
- category: Growth
  name: Failure to Thrive
  frequency: FREQUENT
  description: >-
    Failure to thrive and feeding problems begin in infancy and persist into
    childhood rather than resolving.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common findings are failure to thrive and feeding problems in infancy
      that persist into childhood, gastrointestinal disorders (including
      constipation and gastroesophageal reflux disease
    explanation: >-
      GeneReviews names failure to thrive and its persistence.
- category: Cardiovascular
  name: Congenital Heart Defect
  frequency: OCCASIONAL
  description: >-
    Congenital heart defects occur in about a quarter of individuals and are the most
    severe manifestation of the syndrome. No single lesion predominates, though
    patent ductus arteriosus is the one GeneReviews singles out. The term is bound at
    the umbrella level because the 25% figure is for congenital heart defects as a
    class, not for patent ductus arteriosus specifically.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most severe manifestations were congenital heart defects (25%) and the
      most common were gastrointestinal symptoms (81%).
    explanation: >-
      Gives the 25% figure and the severity ranking.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ocular issues, dental anomalies, and congenital heart defects (especially
      patent ductus arteriosus).
    explanation: >-
      Names congenital heart defects among the common findings and identifies patent
      ductus arteriosus as the lesion most often singled out.
- category: Musculoskeletal
  name: Musculoskeletal Findings
  frequency: VERY_FREQUENT
  description: >-
    Musculoskeletal findings on physical examination are present in about four-fifths
    of individuals, including joint laxity, chest-wall deformity, and long tapering
    fingers. Bound at the umbrella level because the 81% figure covers musculoskeletal
    findings as a class rather than joint hypermobility specifically.
  phenotype_term:
    preferred_term: Abnormality of the musculoskeletal system
    term:
      id: HP:0033127
      label: Abnormality of the musculoskeletal system
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Physical examination revealed a high proportion of musculoskeletal findings
      (81%).
    explanation: >-
      Gives the 81% figure underlying the VERY_FREQUENT band.
  - reference: PMID:15918153
    reference_title: >-
      3q29 microdeletion syndrome: clinical and molecular characterization of a new
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autism, gait ataxia, chest-wall deformity, and long and tapering fingers were
      noted in at least two of six patients.
    explanation: >-
      Documents the specific musculoskeletal features in the original series.
- category: Craniofacial
  name: Mild Facial Dysmorphism
  frequency: FREQUENT
  description: >-
    Dysmorphism is present but subtle — a long narrow face, short philtrum and high
    nasal bridge — and consistent enough across patients to be recognizable, but not
    striking enough to prompt testing on its own.
  evidence:
  - reference: PMID:15918153
    reference_title: >-
      3q29 microdeletion syndrome: clinical and molecular characterization of a new
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotype includes mild-to-moderate mental retardation, with only slightly
      dysmorphic facial features that are similar in most patients: a long and
      narrow face, short philtrum, and high nasal bridge.
    explanation: >-
      Describes both the specific features and their mildness.
- category: Neurologic
  name: Cerebellar Hypoplasia
  description: >-
    Cerebellar vermis hypoplasia and other posterior fossa structural anomalies are
    seen on neuroimaging. Quantitative MRI shows reduced cerebellar cortex volume
    across the group even where no anomaly is flagged qualitatively. No frequency
    band is asserted: neither cited abstract carries a percentage for cerebellar
    hypoplasia specifically, and banding it from the deep-research report's 33% would
    be citing a figure this entry cannot quote.
  phenotype_term:
    preferred_term: Cerebellar hypoplasia
    term:
      id: HP:0001321
      label: Cerebellar hypoplasia
  evidence:
  - reference: PMID:33564151
    reference_title: >-
      Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging revealed structural anomalies of the posterior fossa, but on
      neurological exam study subjects displayed only mild or moderate motor
      vulnerabilities.
    explanation: >-
      Documents posterior fossa anomalies alongside the comparatively mild motor
      examination.
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29Del participants had smaller cerebellar cortex volumes than controls,
      before and after correction for intracranial volume (ICV).
    explanation: >-
      Quantitative confirmation of reduced cerebellar cortical volume.
genetic:
- name: 3q29 recurrent 1.6 Mb deletion
  association: Genetic Mutation
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: DLG1
    term:
      id: hgnc:2900
      label: DLG1
  inheritance:
  - name: Autosomal dominant, typically de novo
  notes: >-
    The causal lesion is the copy-number variant itself, not a point mutation in any
    gene. The gene binding here is nominal — DLG1 is the historical lead candidate
    and lies within the interval — and should not be read as a claim that DLG1 alone
    causes the syndrome. See the discussion on driver-gene attribution.
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of the 3q29 recurrent deletion is established by identification
      of a heterozygous 1.6-Mb deletion at the approximate position of
      chr3:195998129-197623129 in the reference genome (NCBI Build 38).
    explanation: >-
      Defines the deletion by coordinates, which is what the diagnosis rests on.
- name: PAK2
  association: Disease-associated
  relationship_type: COOPERATING
  gene_term:
    preferred_term: PAK2
    term:
      id: hgnc:8591
      label: PAK2
  notes: >-
    An autosomal paralogue of the X-linked intellectual disability gene PAK3, and the
    only gene in the interval with a directly demonstrated functional contribution to
    a measured cellular phenotype — the mitochondrial metabolic-flexibility deficit.
    Curated as contributing rather than causative.
  evidence:
  - reference: PMID:37585521
    reference_title: >-
      Cross-species analysis identifies mitochondrial dysregulation as a functional
      consequence of the schizophrenia-associated 3q29 deletion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These molecular signatures were supported by analysis of oxidative
      phosphorylation protein complex expression in mouse brain and assays of
      mitochondrial function in engineered cell lines, which revealed a lack of
      metabolic flexibility and a contribution of the 3q29 gene PAK2.
    explanation: >-
      The functional attribution that justifies the COOPERATING classification.
- name: NCBP2
  association: Disease-associated
  relationship_type: MODIFIER
  gene_term:
    preferred_term: NCBP2
    term:
      id: hgnc:7659
      label: NCBP2
  notes: >-
    Curated as a modifier rather than a driver, which is the substantive claim from
    the interaction screens: reducing NCBP2 dosage enhances the phenotypes produced
    by the other genes in the interval rather than producing the syndrome itself.
  evidence:
  - reference: PMID:32053595
    reference_title: >-
      NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila
      and Xenopus laevis models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Interestingly, NCBP2 homologs in Drosophila (Cbp20) and X. laevis (ncbp2)
      enhanced the phenotypes of homologs of the other 3q29 genes, leading to
      significant increases in apoptosis that disrupted cellular organization and
      brain morphology.
    explanation: >-
      Establishes the enhancer/modifier role.
diagnosis:
- name: Chromosomal Microarray
  description: >-
    The deletion is submicroscopic and invisible on conventional karyotype, so
    detection requires chromosomal microarray or a targeted copy-number method (FISH,
    MLPA, qPCR). Diagnosis is by identification of the heterozygous 1.6 Mb deletion
    at the recurrent coordinates.
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of the 3q29 recurrent deletion is established by identification
      of a heterozygous 1.6-Mb deletion at the approximate position of
      chr3:195998129-197623129 in the reference genome (NCBI Build 38).
    explanation: >-
      States the diagnostic standard and the coordinates.
- name: Psychiatric and Neurodevelopmental Assessment
  description: >-
    Formal assessment is recommended for every individual with the deletion, not only
    those who look impaired — a point with real consequences, because cognitive
    ability does not predict psychiatric burden here. Someone with an IQ in the
    normal range carries the same requirement for behavioural evaluation as anyone
    else with the deletion. Autism evaluation in particular is argued to be standard
    of care, since autistic features are present in many individuals who do not carry
    an autism diagnosis.
  evidence:
  - reference: PMID:35297118
    reference_title: A distinct cognitive profile in individuals with 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cognitive ability is not a strong indicator of other neurodevelopmental or
      psychiatric impairment; thus, individuals with 3q29 deletion syndrome who
      exhibit IQ scores within the normal range should receive all recommended
      behavioural evaluations.
    explanation: >-
      The explicit recommendation, and the reason for it.
  - reference: PMID:31346402
    reference_title: >-
      Neuropsychiatric phenotypes and a distinct constellation of ASD features in
      3q29 deletion syndrome: results from the 3q29 registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study implies that ASD evaluation should be the standard of care for
      individuals with 3q29Del.
    explanation: >-
      Supports routine autism evaluation regardless of reported diagnosis.
imaging_findings:
- name: Reduced Cerebellar Cortex Volume
  modality: MRI
  description: >-
    Quantitative structural MRI shows smaller cerebellar cortex volume with an
    anterior-posterior gradient, and larger cerebellar white matter volume, relative
    to neurotypical controls.
  located_in:
    preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An anterior-posterior gradient emerged in finer grained lobule-based and
      voxel-wise analyses.
    explanation: >-
      Documents the spatial gradient of the volumetric deficit.
- name: Posterior Fossa Cystic Malformation
  modality: MRI
  description: >-
    Arachnoid cysts and mega cisterna magna occur at elevated rates and independent
    of cerebellar volume. Worth recording precisely because they are the finding most
    likely to be reported as an incidental note — and, unlike the volumetric
    measures, they carry no demonstrated behavioural association.
  located_in:
    preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:38744992
    reference_title: >-
      Structural deviations of the posterior fossa and the cerebellum and their
      cognitive links in a neurodevelopmental deletion syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cerebellar white matter and subregional gray matter volumes were associated
      with visual-perception and visual-motor integration skills as well as IQ, while
      cystic/cyst-like malformations yielded no behavioral link.
    explanation: >-
      Establishes that the cystic findings, unlike the volumetrics, do not predict
      function.
treatments:
- name: Early Speech and Language Therapy
  description: >-
    The earliest recommended intervention, targeting the speech delay that is both
    common and prognostically informative.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Speech Language Therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early speech and language therapy to address speech delays; physical/occupational
      therapy as needed to address motor issues
    explanation: >-
      GeneReviews management guidance naming speech therapy first.
- name: Physical and Occupational Therapy
  description: >-
    Directed at motor issues and at the visual-motor integration and graphomotor
    weakness that are among the most consistent functional deficits.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early speech and language therapy to address speech delays; physical/occupational
      therapy as needed to address motor issues
    explanation: >-
      GeneReviews management guidance for the motor domain.
- name: Psychiatric Care and Cognitive Behavioural Therapy
  description: >-
    Care by a child psychiatrist or psychologist with explicit transfer to adult
    services, plus cognitive behavioural therapy for social disability and anxiety.
    The lifespan framing is the point: the psychiatric risk in this syndrome does not
    end at paediatric discharge, it changes character, with psychosis risk rising as
    anxiety and ADHD are already established.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Behavioral Counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  target_phenotypes:
  - preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      care by a child psychiatrist/psychologist as needed for neuropsychiatric
      disorders with transfer of care to an adult psychiatrist when appropriate;
      cognitive behavioral therapy to address social disability and/or anxiety
    explanation: >-
      GeneReviews guidance including the transition-of-care element.
- name: Symptomatic Pharmacotherapy for Anxiety, ADHD or Psychosis
  description: >-
    Medication is symptomatic. There is no disease-modifying or locus-directed
    therapy, and nothing in the literature reviewed proposes one.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      medication as needed for anxiety, ADHD, or psychosis; standard treatment of
      seizures
    explanation: >-
      GeneReviews guidance for symptomatic pharmacotherapy.
- name: Structured Multisystem Surveillance
  description: >-
    A defined surveillance schedule rather than a therapy, and worth curating
    separately because the schedule is what converts a list of associated findings
    into actionable care: developmental progress, growth, nutrition and feeding at
    every visit; annual neuropsychiatric and scoliosis assessment; annual
    ophthalmology; dental examination every six months.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surveillance: At each visit: monitor developmental progress, educational needs,
      growth, nutrition, and feeding; assess for seizures, gastrointestinal issues,
      otitis, enuresis, and/or sleep issues.
    explanation: >-
      The per-visit surveillance content.
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Annual assessment for neuropsychiatric manifestations and scoliosis; annual
      ophthalmology examination
    explanation: >-
      The annual surveillance content, including the psychiatric assessment that the
      early-onset psychosis risk motivates.
- name: Genetic Counseling
  description: >-
    Counselling covers a recurrence risk structure that is unusual for a dominant
    disorder: because the deletion is typically de novo, sibling recurrence risk is
    below 1% yet above population baseline because of possible parental mosaicism,
    while an affected individual's own offspring risk is 50%.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:27656750
    reference_title: 3q29 Recurrent Deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each child of an individual with the 3q29 recurrent deletion has a 50% chance
      of inheriting the deletion.
    explanation: >-
      The offspring risk figure counselling communicates.
differential_diagnoses:
- name: 3q29 microduplication syndrome
  description: >-
    The reciprocal product of the same non-allelic homologous recombination event at
    the same locus. It shares the mechanism and the interval but is a distinct,
    generally milder disorder — a useful natural dosage comparator rather than a
    diagnostic trap, since microarray distinguishes them unambiguously.
  distinguishing_features:
  - Copy-number gain rather than loss at the same interval
  - Generally milder and more variable phenotype
  evidence:
  - reference: PMID:32874693
    reference_title: Phenotype Heterogeneity in 3q29 Microduplication Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3q29 microduplication syndrome is characterized by widely variable clinical
      presentation, but generally mild features.
    explanation: >-
      Characterizes the reciprocal disorder as milder and more variable, which is the
      distinction this entry draws.
- name: 22q11.2 deletion syndrome
  description: >-
    The other recurrent CNV strongly associated with schizophrenia, and the one this
    syndrome is most often compared with mechanistically — mitochondrial phenotypes
    have been reported for both, raising the possibility of convergent biology
    downstream of distinct CNVs.
  distinguishing_features:
  - Different locus, resolved by microarray
  - Conotruncal cardiac defects, hypoparathyroidism and immunodeficiency are
    characteristic of 22q11.2 and not of this syndrome
animal_models:
- name: 3q29 deletion (Df/+) mouse
  species: Mouse
  genotype: Chromosome-engineered deletion syntenic to the human 3q29 interval
  publication: PMID:31216562
  description: >-
    A chromosome-engineered mouse carrying the syntenic deletion, offering
    construct validity by design and, as it turned out, elements of face and
    predictive validity too.
  modeled_mechanisms:
  - target: Cortical Excitation-Inhibition Imbalance
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Regionally restricted cortical neuronal hyperactivation with reduced
      parvalbumin expression, plus impaired prepulse inhibition that is reversed by
      antipsychotics.
    limitations: >-
      Prepulse inhibition is a sensorimotor gating proxy, not psychosis; a mouse
      cannot model the syndrome's defining psychiatric outcome, and its reversal by
      antipsychotics demonstrates pharmacological responsiveness of the proxy rather
      than of the human illness. Reduced parvalbumin expression is a marker
      measurement, not a demonstration of interneuron loss.
    evidence:
    - reference: PMID:31216562
      reference_title: >-
        Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity
        in a mouse model of 3q29 deletion syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Importantly, the schizophrenia-related impaired prepulse inhibition was
        reversed by administration of antipsychotics.
      explanation: >-
        The predictive-validity observation, recorded together with its limitation.
  evidence:
  - reference: PMID:31216562
    reference_title: >-
      Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity
      in a mouse model of 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      3q29 deletion (Df/+) mice showed reduced body weight and brain volume and,
      more importantly, impaired social interaction and prepulse inhibition.
    explanation: >-
      Establishes the model's phenotypic repertoire, including the growth and brain
      volume correlates of the human syndrome.
- name: CRISPR-engineered 3q29 deletion mouse
  species: Mouse
  genotype: B6.Del16+/Bdh1-Tfrc, CRISPR-engineered syntenic 3q29 deletion
  publication: PMID:30976085
  description: >-
    An independently generated model of the same deletion, used as the in vivo arm of
    the cross-species transcriptomic analysis.
  modeled_mechanisms:
  - target: Mitochondrial and Energy-Metabolism Dysregulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Perinatal isocortex from this model contributed the mouse half of the
      cross-species convergence on mitochondrial and energy-metabolism pathways.
    limitations: >-
      The convergent signature was derived at a single perinatal timepoint in mouse
      and at two timepoints in organoids; neither addresses adult cortex, and the
      metabolic deficit has not been measured in tissue from affected individuals.
    evidence:
    - reference: PMID:37585521
      reference_title: >-
        Cross-species analysis identifies mitochondrial dysregulation as a functional
        consequence of the schizophrenia-associated 3q29 deletion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We profiled transcriptomes from isogenic cortical organoids that were aged
        for 2 and 12 months, as well as perinatal mouse isocortex, all at single-cell
        resolution.
      explanation: >-
        Identifies the mouse tissue and timepoint contributing to the convergence.
- name: Drosophila and Xenopus 3q29 homolog knockdown panel
  species: Drosophila melanogaster and Xenopus laevis
  genotype: Tissue-specific individual and pairwise knockdown of 14 homologs of 3q29 genes
  publication: PMID:32053595
  description: >-
    Not a model of the deletion but a dissection of it: a 314-combination pairwise
    knockdown screen designed to ask which genes in the interval interact, which is
    the question a syntenic deletion model cannot answer.
  modeled_mechanisms:
  - target: Combinatorial Haploinsufficiency Across the 3q29 Interval
    relationship: PERTURBS
    fidelity: LOW
    description: >-
      Systematic pairwise perturbation identified 44 interactions between 3q29 gene
      homolog pairs and 34 with other neurodevelopmental genes, with NCBP2 emerging
      as a broad enhancer acting through apoptosis.
    limitations: >-
      Invertebrate and amphibian homolog knockdown is a screen for interaction
      structure, not a model of human haploinsufficiency; knockdown is not
      hemizygosity, and the eye and brain readouts are not the human phenotypes. The
      finding earns its place because it answers a combinatorial question no
      mammalian deletion model addresses, not because it recapitulates the disease.
    evidence:
    - reference: PMID:32053595
      reference_title: >-
        NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila
        and Xenopus laevis models.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Using the fly eye, we screened for 314 pairwise knockdowns of homologs of
        3q29 genes and identified 44 interactions between pairs of homologs and 34
        interactions with other neurodevelopmental genes.
      explanation: >-
        The scale and result of the interaction screen.
experimental_models:
- name: Isogenic 3q29 deletion human cortical organoids
  experimental_model_type: ORGANOID
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: CRISPR-engineered isogenic induced pluripotent stem cell lines
  publication: PMID:37585521
  description: >-
    Human cortical organoids carrying the full 1.6 Mb deletion introduced by
    CRISPR-Cas9 into a neurotypical iPSC background, profiled by single-cell RNA
    sequencing at 2 and 12 months. The isogenic design is what makes them
    informative: it removes the genetic-background variability that otherwise
    confounds patient-derived comparisons for a variably expressive CNV.
  modeled_mechanisms:
  - target: Mitochondrial and Energy-Metabolism Dysregulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The human half of the cross-species convergence on mitochondrial function and
      energy metabolism in developing cortical tissue.
    limitations: >-
      Organoids model early cortical development and lack vasculature, microglia and
      mature circuit activity, so they cannot address the adolescent-to-adult window
      in which psychosis emerges — the phenotype the finding is ultimately being used
      to explain.
    evidence:
    - reference: PMID:37585521
      reference_title: >-
        Cross-species analysis identifies mitochondrial dysregulation as a functional
        consequence of the schizophrenia-associated 3q29 deletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We interrogated the developing neural transcriptome in two experimental model
        systems with complementary advantages: isogenic human cortical organoids and
        isocortex from the 3q29Del mouse model.
      explanation: >-
        Identifies the organoid system and its role in the cross-species design.
discussions:
- discussion_id: q3q29_driver_gene_attribution
  kind: KNOWLEDGE_GAP
  prompt: >-
    Which gene or combination of genes in the 3q29 interval is responsible for the
    neurodevelopmental and psychiatric phenotype?
  attaches_to:
  - pathophysiology#Combinatorial Haploinsufficiency Across the 3q29 Interval
  rationale: >-
    Two decades after the syndrome was described, no gene in the interval has been
    shown to be necessary and sufficient, and single-gene knockouts of the leading
    candidates do not reproduce it. The evidence points instead at combinatorial
    haploinsufficiency, with NCBP2 acting as an enhancer of other genes' effects and
    PAK2 contributing to a measured metabolic deficit. This gap is what stops the
    entry nominating a driver, and it is not merely academic: a therapeutic strategy
    aimed at one gene presupposes an answer that does not exist. Note also that the
    interval's genes are functionally heterogeneous — synaptic scaffolding, actin
    regulation, mRNA cap binding, ubiquitination and SUMOylation — so "combinatorial"
    here does not yet mean "converging on one pathway".
  proposed_experiments:
  - experiment_id: q3q29_single_gene_rescue_in_isogenic_organoids
    name: Single-gene dosage restoration in isogenic 3q29 deletion organoids
    description: >-
      Restore each interval gene individually and in defined combinations in the
      isogenic deletion organoid background, and test which restorations rescue the
      mitochondrial and transcriptomic phenotypes. A single-gene rescue would
      identify a driver; a requirement for combinations would confirm the
      combinatorial model directly rather than by inference from knockdown screens.
  evidence:
  - reference: PMID:32053595
    reference_title: >-
      NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila
      and Xenopus laevis models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Despite its importance towards neurodevelopment, the role of individual genes,
      genetic interactions, and disrupted biological mechanisms underlying the
      deletion have not been thoroughly characterized.
    explanation: >-
      States the gap directly.
  - reference: DOI:10.1186/s11689-026-09696-y
    reference_title: >-
      Driver or passenger? A new assessment of genes in the schizophrenia-associated
      3q29 deletion locus for contribution to neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Hemizygosity of this set of 22 protein-coding genes significantly increases
      risk for schizophrenia and autism spectrum disorders among other
      neurodevelopmental conditions, but it is not known which genes in this CNV
      interval are responsible for these phenotypes.
    explanation: >-
      A review dedicated to exactly this question, stating that it remains open.
  - reference: DOI:10.1186/s11689-026-09696-y
    reference_title: >-
      Driver or passenger? A new assessment of genes in the schizophrenia-associated
      3q29 deletion locus for contribution to neurodevelopmental disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Our analysis reveals that ubiquitination/SUMOylation stands out among processes
      potentially compromised due to compound haploinsufficiency of four 3q29Del
      genes
    explanation: >-
      Nominates a candidate converging pathway, which is the most concrete current
      answer to the gap and is recorded as such rather than adopted as the mechanism.
- discussion_id: q3q29_psychosis_model_gap
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Does antipsychotic-reversible prepulse-inhibition impairment in the syntenic
    mouse tell us anything about the psychosis risk that defines this syndrome in
    humans?
  attaches_to:
  - pathophysiology#Cortical Excitation-Inhibition Imbalance
  rationale: >-
    The mouse work is genuinely strong on its own terms — construct validity by
    design, a restricted cortical hyperactivation phenotype, reduced parvalbumin
    expression, and a behavioural deficit that antipsychotics reverse. But prepulse
    inhibition is a sensorimotor gating measure, not psychosis, and the drug reversal
    demonstrates that the proxy is pharmacologically responsive rather than that the
    model captures the human illness. The mismatch matters here more than usual
    because the >40-fold schizophrenia risk is the syndrome's signature finding, so
    the phenotype we most want a model for is precisely the one no rodent can carry.
    The cortical excitation-inhibition node is curated at PROVISIONAL confidence for
    this reason.
  proposed_experiments:
  - experiment_id: q3q29_human_cortical_circuit_measures
    name: Human cortical excitation-inhibition measures in deletion carriers
    description: >-
      Apply non-invasive measures of cortical excitation-inhibition balance — for
      example magnetic resonance spectroscopy of GABA and glutamate, or
      TMS-EEG-derived cortical inhibition — in deletion carriers with and without
      psychotic symptoms, to test whether the imbalance the mouse shows has a human
      correlate that tracks psychiatric outcome.
  evidence:
  - reference: PMID:31216562
    reference_title: >-
      Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity
      in a mouse model of 3q29 deletion syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These findings are reminiscent of the growth defects and neuropsychiatric
      behavioral phenotypes in patients with 3q29 deletion syndrome and exemplify
      that the mouse model achieves some part of face validity and predictive
      validity.
    explanation: >-
      The authors' own hedged validity claim, quoted because the hedge is the point.
notes: >-
  Why no driver gene is nominated. The temptation with a contiguous-gene syndrome is
  to pick the most neurologically plausible gene in the interval and treat it as the
  cause. This entry does not, because the functional literature does not support it:
  single-gene knockouts of DLG1 and PAK2 do not reproduce the syndrome, and the one
  gene with a systematic functional result attached (NCBP2) turns out to act as an
  enhancer of the others rather than as a driver. The `genetic` block therefore binds
  DLG1 nominally, purely so the record has a gene handle, with a note saying so, and
  the mechanistic weight sits on a combinatorial node.

  Ontology suggestions from the deep-research report that were wrong and were not
  used. Four, all caught against the local term caches rather than by the report's own
  reference validation, which checks citations only: `hgnc:2905` was given for DLG1
  (correct id `hgnc:2900`), `hgnc:7647` for NCBP2 (correct id `hgnc:7659`),
  `HP:0002571` for retrocerebellar cyst (that identifier is Achalasia), and
  `HP:0031466` for executive-function deficits (offered by the report itself as an
  approximation). Executive-function deficit and graphomotor weakness are curated in
  prose rather than bound to an approximate HPO term.

  References fetched but not cited. Two cached records were dropped rather than left
  stranded in the commit. `DOI:10.1126/sciadv.adh0558` is the same paper as
  `PMID:37585521`, which the entry cites. `PMID:33819264` is a two-hit functional
  study of the **16p12.1** deletion, not this locus; the deep-research report cited it
  as a methodological follow-on, but curating it here would attach a different
  disorder's evidence to this one. `PMID:29884173` is the study protocol for the
  cohort whose results are cited via `PMID:33564151`, and is retained in the cache
  without a citation as provenance for that cohort.

  Scope. The reciprocal 3q29 microduplication is a distinct disorder and is recorded
  here only as a differential, not as a subtype. No `datasets:` block is included:
  relevance triage for accessions is a manual step that was not performed, and it
  would be particularly error-prone here, since the interval's gene names retrieve
  large volumes of unrelated cell-biology data.
references:
- reference: PMID:27656750
  title: 3q29 Recurrent Deletion.
  tags:
  - GeneReviews
- reference: PMID:15918153
  title: >-
    3q29 microdeletion syndrome: clinical and molecular characterization of a new
    syndrome.
- reference: PMID:20691406
  title: Microdeletions of 3q29 confer high risk for schizophrenia.
- reference: PMID:26055425
  title: >-
    The 3q29 deletion confers >40-fold increase in risk for schizophrenia.
- reference: PMID:33564151
  title: >-
    Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
- reference: PMID:34131099
  title: >-
    Convergent and distributed effects of the 3q29 deletion on the human neural
    transcriptome.
- reference: DOI:10.1186/s11689-026-09696-y
  title: >-
    Driver or passenger? A new assessment of genes in the schizophrenia-associated
    3q29 deletion locus for contribution to neurodevelopmental disorders.
- reference: PMID:37585521
  title: >-
    Cross-species analysis identifies mitochondrial dysregulation as a functional
    consequence of the schizophrenia-associated 3q29 deletion.
📚

References & Deep Research

References

8
PMID:27656750
3q29 Recurrent Deletion.
No top-level findings curated for this source.
PMID:15918153
3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome.
No top-level findings curated for this source.
PMID:20691406
Microdeletions of 3q29 confer high risk for schizophrenia.
No top-level findings curated for this source.
PMID:26055425
The 3q29 deletion confers >40-fold increase in risk for schizophrenia.
No top-level findings curated for this source.
PMID:33564151
Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care.
No top-level findings curated for this source.
PMID:34131099
Convergent and distributed effects of the 3q29 deletion on the human neural transcriptome.
No top-level findings curated for this source.
DOI:10.1186/s11689-026-09696-y
Driver or passenger? A new assessment of genes in the schizophrenia-associated 3q29 deletion locus for contribution to neurodevelopmental disorders.
No top-level findings curated for this source.
PMID:37585521
Cross-species analysis identifies mitochondrial dysregulation as a functional consequence of the schizophrenia-associated 3q29 deletion.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Chromosome 3q29 Microdeletion Syndrome: Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 23 citations 2026-08-15T19:16:37.028156

Chromosome 3q29 Microdeletion Syndrome: Comprehensive Research Report

1. Disease Information

Overview

Chromosome 3q29 microdeletion syndrome (3q29Del) is a recurrent genomic disorder caused by a heterozygous, typically de novo, ~1.6 Mb deletion at cytoband 3q29 (chr3:195,998,129–197,623,129, GRCh38), mediated by nonallelic homologous recombination (NAHR) between flanking low-copy repeats (LCRs) [Willatt et al., Am J Hum Genet, 2005, PMID:15918153]. It was first delineated as a distinct clinical entity in 2005 in a report of six unrelated patients: "3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome" — the deletion was shown to be a recurrent, LCR-flanked rearrangement distinguishable from earlier, non-recurrent 3q29 deletions reported since 2001. The syndrome is now recognized as one of the strongest-effect genetic risk factors for schizophrenia identified to date (odds ratio >40), alongside a broad, highly variable neurodevelopmental, psychiatric, and multisystem medical phenotype.

Key Identifiers

Resource Identifier
OMIM (deletion) #609425 — Chromosome 3q29 deletion syndrome
OMIM (reciprocal duplication) #611936 — Chromosome 3q29 duplication syndrome
Orphanet ORPHA:65286
MONDO MONDO:0012269 (chromosome 3q29 microdeletion syndrome)
MedGen C2674949
GeneReviews NBK385289 ("3q29 Recurrent Deletion")
ICD-10 Q93.5 (other deletions of part of a chromosome) — no dedicated ICD-10/11 code; captured under chromosomal microdeletion syndromes NEC
Suggested MONDO cross-term MONDO:0012269

Synonyms / Alternative Names

  • 3q29 deletion syndrome
  • 3q29 microdeletion syndrome
  • Del(3)(q29)
  • Monosomy 3q29
  • DEL3q29 (registry/lay shorthand)

Data Source Character

Knowledge of this syndrome derives almost entirely from aggregated, deeply-phenotyped disease-level cohort resources, not incidental EHR mining — chiefly the Emory 3q29 Registry / 3q29 Project (3q29deletion.org; >100 enrolled families as of the mid-2020s; study protocol PMID:29884173), which recruits via self-referral and performs direct, in-person, gold-standard psychiatric/cognitive/medical assessment (e.g., the "Deep phenotyping" cohort of 32 individuals, PMID:33564151). This is supplemented by population-ascertainment studies (Icelandic deCODE cohort, UK Biobank) that establish prevalence and baseline penetrance independent of clinical ascertainment bias, and by case-control CNV burden studies in schizophrenia cohorts (PGC, GAIN, Ashkenazi Jewish cohort) that established the psychiatric risk association.

2. Etiology

Disease Causal Factor

3q29Del is caused entirely by genomic structural variation — a hemizygous deletion of ~21–22 protein-coding genes at 3q29 — not by infectious, purely environmental, or classical single-gene point-mutation mechanisms. It is a genomic disorder in the same mechanistic class as 22q11.2, 16p11.2, and 1q21.1 deletion syndromes.

Molecular/Mechanistic Basis

  • NAHR between LCRs: The deletion arises from unequal crossing-over between misaligned low-copy repeats flanking the 3q29 region during meiosis, producing a highly recurrent ~1.6 Mb deletion with near-identical breakpoints across unrelated patients (GeneReviews, NBK385289).
  • The reciprocal NAHR product is the 3q29 microduplication (OMIM #611936), providing a natural "dosage" comparator.

Genetic Risk Factors

  • The deletion itself is the causal lesion — there is no known additional germline variant required for the deletion to arise (it is a de novo structural mutation in most cases).
  • Genetic modifiers of expressivity: No single gene within the interval is necessary and sufficient for the full phenotype; mouse single-gene knockouts of Dlg1 or Pak2 alone fail to recapitulate the syndrome, supporting a polygenic/oligogenic model within the CNV in which multiple genes (candidates: DLG1, PAK2, NCBP2, and the ubiquitination/SUMOylation gene cluster UBXN7, FBXO45, RNF168, SENP5) act combinatorially [Rump et al./PLOS Genetics 2020, PMID:32053595; Journal of Neurodevelopmental Disorders 2026, "Driver or passenger?"].
  • Polygenic background: Oetjens et al. (Nat Commun, 2019;10:4897) quantified a measurable contribution of genome-wide common-variant polygenic burden to variable expressivity across 11 rare CNV/monogenic disorders including 3q29Del, indicating that background common-variant load modulates phenotypic severity on top of the CNV.
  • Parental origin/mosaicism: A minority (~7% of tested families) of cases are inherited from an unaffected or mildly affected parent; germline/somatic mosaicism has been documented, giving simplex families a low (<1%, but above general-population) recurrence risk.

Environmental Risk Factors

No specific environmental cause or trigger for the deletion event itself has been identified (as with other NAHR-mediated CNVs, advanced parental age has been hypothesized as a general risk factor for de novo CNVs but is not specifically established for 3q29). No teratogenic, toxin, or infectious contributor is documented.

Protective Factors

No genetic or environmental protective factor against deletion occurrence or phenotype severity is established. Reduced penetrance is observed (unaffected or mildly-affected transmitting parents exist), but the modifiers of this reduced penetrance (aside from polygenic background, above) are not yet characterized.

Gene-Environment Interactions

Not established for this syndrome; the literature to date is dominated by CNV-dosage and within-locus gene-gene interaction studies (Drosophila/Xenopus pairwise-interaction screening, PMID:32053595) rather than classical GxE analysis.

3. Phenotypes

3q29Del produces a highly pleiotropic, variably expressive phenotype spanning neurodevelopmental, neuropsychiatric, gastrointestinal, cardiac, musculoskeletal, craniofacial, ophthalmologic, dental, and neuroradiological domains. The most systematic data come from the Emory "Deep phenotyping" study of 32 directly-assessed individuals (Sanchez Russo et al., Genet Med, 2021;23(5):872–880, PMID:33564151) and the companion cognitive/registry studies.

Neurodevelopmental

Phenotype Frequency Suggested HPO term
Developmental delay 70–90% HP:0001263 Global developmental delay
Intellectual disability (mild–moderate) 30–40% (34% in deep-phenotyping cohort) HP:0001256 Intellectual disability, mild
Speech/language delay ~60% HP:0000750 Delayed speech and language development
Motor delay / hypotonia (infancy) ~34% HP:0001290 Generalized hypotonia
Executive function deficits 46–47% HP:0031466 Impairment in personality function (or free-text)
Graphomotor weakness 78% HP:0011936 (fine motor delay proxy)
Distinct cognitive profile: verbal > nonverbal strength (mean FSIQ 73, range 40–99; verbal mean 80 vs. nonverbal mean 75) n=32 cohort —

Neuropsychiatric (onset typically childhood–young adulthood; can present earlier than population norms)

Phenotype Frequency HPO term
ADHD 63% HP:0007018 Attention deficit hyperactivity disorder
Anxiety disorder 40% HP:0000739 Anxiety
Autism spectrum disorder 29–38% (registry: 29.0% vs. 1.47% general population, p<2.2×10⁻¹⁶; deep-phenotyping cohort: 37.5%) HP:0000729 Autistic behavior
Psychotic disorder / schizophrenia spectrum ~19–20% (>40-fold increased risk vs. population) HP:0000709 Psychosis
Prodromal psychosis 14% —
Bipolar disorder with psychosis reported HP:0007302

Distinct ASD phenotype: individuals with 3q29Del show a reduced male:female ratio for autism (2:1 vs. typical 4:1) and a distinctive profile of substantially elevated Restricted Interests and Repetitive Behaviors with comparatively milder Social Motivation impairment relative to idiopathic autism [Pollak et al., Molecular Autism, 2019;10:30, PMID:31346402].

Gastrointestinal (most common medical system involved, ~81–84%)

  • Feeding difficulty in infancy (latching problems) — often first presenting sign
  • Gastroesophageal reflux — ~50%
  • Chronic constipation — ~41%
  • Failure to thrive — ~44%
  • HPO: HP:0011968 Feeding difficulties; HP:0002020 Gastroesophageal reflux; HP:0002019 Constipation; HP:0001508 Failure to thrive

Cardiac

  • Congenital heart defects — 25%, no single predominant lesion; patent ductus arteriosus most frequent, also reported: ventricular septal defect, pulmonary stenosis/atresia, tricuspid stenosis, hypoplastic right heart
  • HPO: HP:0001631 Atrial septal defect; HP:0001643 Patent ductus arteriosus; HP:0004415 Hypoplastic right heart

Musculoskeletal (~84%)

  • Joint laxity, chest wall deformity (pectus), long/tapering fingers, scoliosis (screened annually)
  • HPO: HP:0001382 Joint hypermobility; HP:0000768 Pectus carinatum; HP:0100807 Long fingers

Craniofacial (subtle dysmorphism)

  • Long/narrow face, short philtrum, high nasal bridge, prominent forehead, wide/prominent nasal tip, thin upper lip vermilion
  • HPO: HP:0000343 Long philtrum (or short, per source); HP:0000426 Prominent nasal bridge; HP:0000219 Thin vermilion border

Ophthalmologic (59%)

  • Strabismus (28%), other ocular anomalies
  • HPO: HP:0000486 Strabismus

Dental (41%) and Otologic

  • Dental anomalies; recurrent otitis media (~22%)
  • HPO: HP:0000164 Abnormality of the dentition; HP:0000388 Otitis media

Neuroradiological (posterior fossa; ~71% abnormal on MRI, n=24)

  • Cerebellar vermis hypoplasia — 33%
  • Retrocerebellar arachnoid cyst / mega cisterna magna — 29%
  • Reduced cerebellar cortex volume, increased cerebellar white matter volume vs. controls [Sanders et al./Mol Psychiatry 2024, PMID:38744992]; cerebellar volumetrics correlate with visuomotor and IQ measures
  • HPO: HP:0001321 Cerebellar hypoplasia; HP:0002571 Retrocerebellar cyst

Other

  • Reduced birth weight/postnatal growth deficits; enuresis (~22–25%); sleep disturbance (~31%); seizures (~13%, generally mild/treatment-responsive) — HPO: HP:0001518 Small for gestational age; HP:0000805 Enuresis; HP:0001250 Seizure

Quality of Life

No syndrome-specific EQ-5D/SF-36 dataset exists; qualitative registry data emphasize substantial functional burden from the combination of GI symptoms, executive dysfunction, and psychiatric comorbidity, with caregiver-reported reduced adaptive behavior even in carriers not meeting formal ID criteria.

4. Genetic/Molecular Information

Causal Locus

  • Region: 3q29, chr3:195,998,129–197,623,129 (GRCh38); ~1.6 Mb (older coordinate sets: chr3:195,756,054–197,344,665, GRCh37)
  • Gene content: 21–22 protein-coding genes, plus noncoding transcripts. Confirmed gene list within the canonical interval: TFRC, ZDHHC19, SLC51A, PCYT1A, TCTEX1D2, UBXN7, RNF168, C3orf43 (WDR53-adjacent), WDR53, FBXO45, NRROS, CEP19, PIGX, PAK2, SENP5, NCBP2, NCBP2-AS2, PIGZ, MFI2, MFI2-AS1, DLG1, DLG1-AS1, plus intervening lincRNAs (e.g., LINC00885) and MIR4797.
  • No single gene has been definitively established as necessary and sufficient (no monogenic "driver" confirmed); current models favor combinatorial/oligogenic haploinsufficiency (HGNC-suggested key genes below).

Candidate/Leading Genes

Gene HGNC Function Evidence
DLG1 (Disks large homolog 1 / SAP97) hgnc:2905 MAGUK scaffold; trafficking of AMPA/NMDA glutamate receptors to synaptic membrane; autosomal paralog of X-linked ID gene DLG3 Candidate since original 2005 report; PMID:15918153
PAK2 (p21-activated kinase 2) hgnc:8591 Actin cytoskeleton remodeling; neuronal migration, neurite outgrowth, dendritic spine morphogenesis; autosomal paralog of X-linked ID gene PAK3 PAK2 haploinsufficiency linked to synaptic cytoskeleton impairment and autism-related behavior in model systems
NCBP2 (Nuclear cap-binding protein subunit 2 / CBP20) hgnc:7647 Component of the nuclear cap-binding complex; mRNA processing/export Acts as a key genetic modifier/enhancer of neurodevelopmental phenotypes of other 3q29 gene homologs in Drosophila/Xenopus screens [PMID:32053595]
UBXN7, FBXO45, RNF168, SENP5 hgnc:29076; hgnc:24129; hgnc:20620; hgnc:20351 Ubiquitination/SUMOylation pathway components; RNF168 is causal for RIDDLE syndrome (DNA-damage response) Compound haploinsufficiency across this 4-gene cluster implicated as a converging pathway in the 2026 "Driver or passenger?" reassessment
PIGX, PIGZ hgnc:23443; hgnc:30288 GPI-anchor biosynthesis Included in interval; not individually linked to core phenotype
TFRC hgnc:11763 Transferrin receptor, cellular iron uptake Boundary gene, used to define mouse syntenic deletion (Bdh1–Tfrc interval)
CEP19 hgnc:29020 Centrosomal/ciliary protein; implicated in obesity Candidate for microduplication-associated obesity phenotype

Pathogenic Variant Classification

  • Variant class: Contiguous-gene microdeletion (structural/copy-number variant), not point mutation. ACMG/AMP CNV classification: Pathogenic per ClinGen dosage sensitivity criteria (recurrent LCR-mediated CNV with established gene-dosage disease association).
  • Origin: Overwhelmingly de novo (~93% of tested trios); ~7% inherited from a parent (who may be subclinically affected or mosaic).
  • Allele frequency: Extremely rare in population reference databases — population-based ascertainment (Iceland: 3/101,655; UK Biobank: 5/152,728) yields a population prevalence estimate of ~1:30,000–1:40,000; the CNV is not expected/observed at appreciable frequency in gnomAD-SV given its severe, penetrant phenotype and largely de novo occurrence.
  • Functional consequence: Loss-of-function via hemizygous gene-dosage reduction (haploinsufficiency) across the ~21-gene interval, not a single-protein structural defect.
  • Somatic vs. germline: Germline (constitutional) CNV; documented instance of parental germline/somatic mosaicism.

Modifier Genes

As above — NCBP2 as an enhancer/modifier of other 3q29 homolog phenotypes in Drosophila/Xenopus; genome-wide polygenic background (Oetjens et al. 2019) as a quantitative modifier of expressivity.

Epigenetic Information

No syndrome-specific DNA methylation or histone-modification signature has yet been reported in the literature to date; this remains an open area (unlike more established "episignature" CNV syndromes such as 22q11.2DS).

Chromosomal Abnormality Detail

  • Recurrent, NAHR-mediated, LCR-flanked microdeletion — not detectable by conventional G-banded karyotype; requires chromosomal microarray (CMA), FISH, MLPA, or qPCR for detection/confirmation.
  • Reciprocal microduplication (OMIM #611936) at the same locus produces a distinct, generally milder but still variable phenotype (see below).

5. Environmental Information

No established environmental causal, exacerbating, or infectious factor has been identified for 3q29Del as a genomic disorder — the deletion event itself is a de novo (or rarely inherited) meiotic NAHR event, not environmentally triggered. There is no documented lifestyle, toxin, occupational, or infectious contributor to either deletion occurrence or phenotypic severity in the current literature. This is consistent with other NAHR-mediated recurrent microdeletion syndromes, where the LCR architecture of the locus — not exogenous exposure — is the primary determinant of recurrence.

6. Mechanism / Pathophysiology

Causal Chain (Genomic Lesion → Clinical Phenotype)

  1. Meiotic NAHR between LCRs flanking 3q29 → recurrent ~1.6 Mb hemizygous deletion (biological_scale: MOLECULAR)
  2. Combinatorial/dose-dependent loss of multiple functionally-connected genes (DLG1, PAK2, NCBP2, and the ubiquitination/SUMOylation cluster UBXN7/FBXO45/RNF168/SENP5) → convergent disruption of synaptic scaffolding, cytoskeletal dynamics, mRNA processing, and protein quality-control pathways (biological_scale: MOLECULAR/CELLULAR)
  3. Mitochondrial dysregulation and impaired metabolic flexibility: cross-species transcriptomic analysis (CRISPR-engineered mouse cortex + isogenic human cortical organoids) found 176 concordantly differentially-expressed genes in excitatory neurons across species, converging on mitochondrial function/energy metabolism pathways, with PAK2 implicated as a contributor to the metabolic-flexibility deficit [Purcell/Sefik et al., Sci Adv, 2023;9(33):eadh0558, PMID:37585521]
  4. Synaptic and cytoskeletal dysfunction: DLG1/PAK2 loss impairs AMPA/NMDA receptor trafficking and dendritic spine morphogenesis (CELLULAR)
  5. Cortical excitatory/inhibitory imbalance: mouse model shows abnormally increased excitatory neural activity concentrated in auditory cortex, elevated immediate-early genes (Egr2, Fos, Cyr61, Nr4a1, Btg2, Dusp1), and decreased parvalbumin-positive interneuron density in sensory cortex [Baba et al., Neuropsychopharmacology, 2019;44(12):2125–2135, PMID:31216562] (CELLULAR/TISSUE)
  6. Cerebellar/posterior fossa developmental disruption: reduced cerebellar cortical volume with increased white matter volume, associated with visuomotor/cognitive deficits (TISSUE)
  7. Convergent behavioral/psychiatric output: impaired prepulse inhibition (schizophrenia-relevant), reduced social interaction (autism-relevant), repetitive grooming, impaired fear learning, elevated startle in mouse models — mapping onto the human ADHD/anxiety/ASD/psychosis spectrum (ORGANISM)

Molecular Pathways

  • Synaptic scaffolding / glutamatergic signaling (DLG1-MAGUK family) — GO:0098794 postsynapse; GO:0007626 locomotory behavior (proxy)
  • Rho-family GTPase / PAK2 actin cytoskeleton signaling — GO:0007169; GO:0030036 actin cytoskeleton organization
  • mRNA cap-binding complex / nuclear export (NCBP2) — GO:0000339 RNA cap binding
  • Ubiquitin-proteasome/SUMOylation pathway (UBXN7, FBXO45, RNF168, SENP5) — GO:0016567 protein ubiquitination; GO:0016925 protein sumoylation
  • Mitochondrial oxidative phosphorylation / energy metabolism — GO:0006119 oxidative phosphorylation

Cellular Processes

  • Neuronal migration, neurite outgrowth, dendritic spine morphogenesis (PAK2)
  • Synaptic receptor trafficking (DLG1)
  • DNA-damage response (RNF168 — also causal for RIDDLE syndrome)
  • Cell-cycle and apoptosis regulation (implicated by NCBP2 interaction screens)

Protein Dysfunction

Not classical misfolding/aggregation — mechanism is gene-dosage reduction (haploinsufficiency) across multiple interacting proteins rather than a single mutant protein's structural defect.

Immune System Involvement

NRROS (negative regulator of reactive oxygen species) lies within the deletion interval and has an immune-regulatory role, but no immune/autoinflammatory phenotype has been robustly linked to 3q29Del in human cohorts to date; this remains an underexplored area.

Molecular Profiling

  • Transcriptomics: "Convergent and distributed effects of the 3q29 deletion on the human neural transcriptome" (Transl Psychiatry, 2021;11:344, PMC8206125) — profiled iPSC-derived neural models; found both convergent (multi-gene) and gene-distributed transcriptomic signatures.
  • Single-cell/cross-species: single-cell RNA-seq of cortical organoids (2 and 12 months) and mouse isocortex identifying excitatory-neuron-specific, cross-species-concordant mitochondrial/energy-metabolism dysregulation (PMID:37585521).
  • Model-system functional screening: systematic pairwise interaction screen of 14 3q29 gene homologs (314 pairwise combinations) in Drosophila and Xenopus laevis, identifying NCBP2 as a broad enhancer/modifier (PMID:32053595), and a follow-on "two-hit" functional model paper (PMC8049494).

Suggested Ontology Terms

  • GO (biological process): GO:0007268 chemical synaptic transmission; GO:0030182 neuron differentiation; GO:0016192 vesicle-mediated transport; GO:0006457 protein folding/quality control (proxy for ubiquitin pathway)
  • CL (cell type): CL:0000679 glutamatergic neuron; CL:0000617 GABAergic interneuron (parvalbumin-positive: CL:0000846 parvalbumin GABAergic interneuron); CL:0002605 astrocyte (cortical organoid context)
  • UBERON: UBERON:0002037 cerebellum; UBERON:0001950 neocortex

7. Anatomical Structures Affected

Organ Level

  • Primary: Central nervous system (cerebral cortex, cerebellum/posterior fossa) — UBERON:0000955 brain
  • Secondary/systemic: Heart (UBERON:0000948), gastrointestinal tract (UBERON:0005409), eye (UBERON:0000970), skeletal system (UBERON:0001434), craniofacial skeleton (UBERON:0002516), teeth (UBERON:0003688), middle ear (UBERON:0001846)
  • Body systems involved: Nervous, psychiatric/behavioral, cardiovascular, digestive, musculoskeletal, ophthalmologic, dental/craniofacial, otologic, genitourinary (enuresis)

Tissue/Cell Level

  • Cerebellar cortex (reduced volume) and cerebellar white matter (increased volume) — UBERON:0002129 cerebellar cortex; UBERON:0002978 cerebellar white matter
  • Sensory/auditory cortex — hyperexcitability locus in mouse model
  • Parvalbumin-positive GABAergic interneurons (CL:0000846) — reduced density in sensory cortex
  • Excitatory (glutamatergic) cortical neurons (CL:0000679) — locus of convergent transcriptomic/mitochondrial dysregulation

Subcellular Level

  • Mitochondria (GO:0005739 cellular component) — dysregulated energy metabolism/oxidative phosphorylation
  • Postsynaptic density (GO:0014069) — DLG1/MAGUK scaffold disruption
  • Nucleus (nuclear cap-binding complex, NCBP2) — GO:0005849 mRNA cleavage/cap-binding complex
  • Actin cytoskeleton (PAK2) — GO:0015629

Localization

  • Bilateral, generally symmetric involvement (posterior fossa cystic/hypoplastic findings, cortical volumetric changes) — no strong lateralization reported.

8. Temporal Development

Onset

  • Congenital/prenatal: Reduced birth weight is a recognized early feature; the CNV itself is present from conception (germline/de novo constitutional event).
  • Infancy: Feeding difficulties, hypotonia, motor delay, failure to thrive typically present first.
  • Childhood: Developmental delay, speech delay, ASD, ADHD, anxiety diagnoses emerge.
  • Adolescence–young adulthood: Psychotic disorders/schizophrenia-spectrum illness onset — notably, age at onset for psychosis/prodrome can be younger than typical population onset, with case reports of onset in children as young as 5–10 years compared to the typical 20–25-year window (GeneReviews, NBK385289; Frontiers 2026 case report, "Early-onset psychosis as a sentinel manifestation of 3q29 deletion syndrome").

Progression

  • Neurodevelopmental features (ID, ASD, executive dysfunction) are generally stable/lifelong rather than progressive.
  • Psychiatric features (anxiety, ADHD, psychosis) can be episodic or progressive, with psychosis sometimes evolving from a prodromal phase.
  • GI and musculoskeletal features are largely stable, chronic issues managed symptomatically; scoliosis is monitored for progression.
  • No degenerative/regressive natural-history pattern has been described; this is a static structural genomic lesion producing a developmental, largely non-progressive disorder trajectory at the molecular level, with psychiatric-symptom-level fluctuation.

Patterns

  • Remission: Psychiatric symptoms may partially remit with treatment (e.g., antipsychotics for psychosis) but treatment resistance is a recognized feature (see Treatment section).
  • Critical periods: Early childhood is emphasized as a window for early intervention (speech/OT/PT); adolescence is emphasized as a critical surveillance window for psychosis-prodrome monitoring, particularly around stimulant initiation for ADHD.

9. Inheritance and Population

Epidemiology

  • Prevalence: ~1:30,000 to 1:40,000, derived from two independent population-ascertainment cohorts:
  • Iceland (deCODE, Stefansson et al.): 3 of 101,655 individuals
  • UK Biobank (Kendall et al., 2017): 5 of 152,728 individuals
  • No incidence (birth-rate) data separate from prevalence have been specifically published; given the largely de novo, non-lethal nature of the CNV, birth prevalence and population prevalence are expected to be similar.

Inheritance Pattern

  • Autosomal dominant, virtually always via a de novo structural mutation (~93% of tested trios de novo; ~7% inherited).
  • Penetrance: Incomplete — apparently unaffected transmitting parents have been documented, though when comprehensively assessed some carry substantial subclinical neuropsychiatric morbidity (e.g., a reported transmitting parent with undiagnosed schizoaffective disorder, ADHD, panic disorder, social anxiety, and executive dysfunction), suggesting ascertainment-dependent apparent penetrance rather than true non-penetrance.
  • Expressivity: Highly variable, even within families (multiplex family case report, PMID:32321479), consistent with a polygenic-background modifier model.
  • Genetic anticipation: Not established/reported (mechanism is CNV, not repeat expansion).
  • Germline mosaicism: Documented in at least one reported case (paternal).
  • Founder effects: Not applicable — this is a recurrent NAHR-mediated CNV (mechanistically analogous across populations via shared LCR architecture) rather than a population-specific founder mutation.
  • Consanguinity: Not a relevant risk factor (dominant CNV mechanism, not recessive).
  • Carrier frequency: Equivalent to prevalence given the dominant, largely de novo mechanism (~1:30,000–1:40,000); no population-specific carrier screening data.

Population Demographics

  • No strong evidence for ethnic/geographic enrichment; cases reported across European (Icelandic, UK), North American, and other ancestries via registry/case-report literature.
  • Sex ratio: Roughly equal for the syndrome overall (registry cohort ~58% male, reflecting general ascertainment rather than a skewed disease ratio); notably the ASD sub-phenotype shows an attenuated male excess (2:1 vs. population 4:1).
  • Age distribution: Registry cohorts span infancy through middle adulthood (deep-phenotyping cohort ages 4.85–39.1 years; ASD-registry cohort ages 0.1–41 years), reflecting the syndrome's lifelong, non-lethal natural history.

10. Diagnostics

First-Line Genetic Test

  • Chromosomal microarray analysis (CMA) (oligonucleotide- or SNP-array-based) — first-tier test, ~100% sensitivity for the canonical deletion in the proband; standard of care per GeneReviews.
  • Routine G-banded karyotype cannot detect this microdeletion.

Confirmatory / Family Testing

  • FISH (fluorescence in situ hybridization)
  • Quantitative PCR (qPCR)
  • Multiplex ligation-dependent probe amplification (MLPA) — used to confirm the deletion in the proband and to test parents/relatives for inheritance status and recurrence-risk counseling.

Additional Recommended Work-Up After Diagnosis (per GeneReviews management guidelines)

  • Developmental/neuropsychological evaluation (cognitive ability, ASD screening, executive function) — gold-standard instruments as used in registry studies (e.g., ADOS-2, cognitive batteries)
  • Psychiatric evaluation for ADHD, anxiety, and prodromal psychosis screening
  • Brain MRI (posterior fossa/cerebellum evaluation)
  • Ophthalmology examination (strabismus, refractive error)
  • Dental evaluation
  • Echocardiography (congenital heart disease screening)
  • Audiology/otolaryngology assessment
  • Skeletal (scoliosis) screening

Clinical Criteria / Differential Diagnosis

No syndrome-specific clinical diagnostic criteria exist independent of the molecular deletion — diagnosis is definitionally genetic (CMA-confirmed 1.6 Mb 3q29 deletion). The clinical differential is broad given the nonspecific combination of developmental delay, learning problems, and neuropsychiatric disorders, overlapping with other genomic disorders (22q11.2DS, 16p11.2, 1q21.1, idiopathic ASD/ID) — CMA is diagnostic and discriminating.

Screening

No population-based newborn or carrier screening program exists for 3q29Del (it is not part of standard NBS panels, being a structural CNV rather than a metabolic/biochemical target). Prenatal detection occurs incidentally via CMA performed for other indications (e.g., abnormal ultrasound, advanced maternal age) or genome-wide NIPT/prenatal microarray.

Suggested LOINC/Test Concepts

  • Chromosomal microarray analysis — LOINC concepts for cytogenomic (SNP) array
  • FISH analysis
  • Echocardiogram (structural heart evaluation)
  • Brain MRI (posterior fossa protocol)

11. Outcome / Prognosis

Survival and Mortality

No elevated mortality rate specific to 3q29Del has been reported in the literature; life expectancy is not documented as reduced, and the condition is not associated with a lethal natural history. Serious cardiac malformations (25% of cases) may carry surgical/perioperative risk in the most severe subset, but no syndrome-wide mortality statistics have been published.

Morbidity and Function

  • Substantial cumulative morbidity from the combination of intellectual disability (34%), ASD (29–38%), ADHD (63%), anxiety (40%), and psychotic disorder (19–20%), plus chronic GI symptoms (81%) and musculoskeletal findings (84%).
  • Distinct cognitive profile (verbal strength relative to nonverbal ability) can mask underlying deficits and complicate school/vocational planning.
  • Quality-of-life burden is not yet quantified with standardized instruments (EQ-5D/SF-36) in a syndrome-specific study; qualitative registry/caregiver data emphasize functional impact from executive dysfunction and psychiatric comorbidity.

Complications

  • Psychosis, when it occurs, appears particularly treatment-resistant — a recognized clinical vulnerability (see Treatment).
  • Feeding/GI complications can necessitate gastrostomy-tube support in severe infantile presentations.
  • Scoliosis and other musculoskeletal complications require ongoing orthopedic monitoring.

Recovery / Disease Course

  • Neurodevelopmental impairments are lifelong (non-regressive); developmental/educational interventions can improve functional trajectory but do not "cure" the underlying deficits.
  • Psychiatric symptoms are managed but not curatively resolved; some individuals achieve good symptom control with combination pharmacotherapy.

Prognostic Factors

  • Presence/severity of congenital heart disease and degree of intellectual disability are the most clinically apparent prognostic modifiers of early-life morbidity.
  • Polygenic background burden is an emerging, quantifiable modifier of overall phenotypic severity (Oetjens et al. 2019) but is not yet a clinical prognostic tool.
  • No validated molecular biomarker currently predicts psychosis conversion risk within 3q29Del carriers (an active area of the field, analogous to 22q11.2DS psychosis-risk biomarker research).

12. Treatment

There is no disease-modifying or curative treatment for 3q29Del; management is entirely symptomatic, multidisciplinary, and surveillance-based, following the GeneReviews consensus management recommendations.

Pharmacotherapy

  • ADHD: Cautious use of stimulants, with explicit monitoring for emerging/exacerbated psychotic symptoms; non-stimulant alternatives (e.g., bupropion, atomoxetine) are suggested as potentially lower-risk options relative to amphetamines/methylphenidate given the elevated psychosis risk in this population.
  • Suggested NCIT: NCIT:C15986 Pharmacotherapy; therapeutic_agent candidates — atomoxetine (CHEBI), bupropion (CHEBI)
  • Anxiety: Standard anxiolytic pharmacotherapy plus cognitive behavioral therapy (see Behavioral, below).
  • Antipsychotics for psychosis: Risperidone has documented use, with variable efficacy and a notable adverse-effect burden (excessive daytime sedation) limiting maintenance dosing; combination therapy (e.g., lurasidone + olanzapine) has achieved sustained stabilization in reported cases without escalation to clozapine [Karger Neuropsychobiology, 2026, "Response to Treatment in 3q29 Deletion Syndrome-Associated Psychosis: A Mini-Review"]. Clozapine is recommended as the treatment of choice when other antipsychotic trials fail, reflecting a described vulnerability to treatment-resistant psychosis in this population.
  • Suggested NCIT therapeutic_agent terms: risperidone (NCIT:C29127), clozapine, olanzapine, lurasidone
  • Seizures: Standard antiepileptic management; seizures in 3q29Del are generally described as mild and treatment-responsive.

Surgical / Interventional

  • Cardiac surgical repair as indicated by specific structural lesion (e.g., PDA closure, VSD repair) — NCIT:C15329 Surgical Procedure
  • Gastrostomy tube placement for severe feeding/failure-to-thrive presentations
  • Orthopedic surgical intervention for progressive scoliosis when indicated — NCIT:C16186 Orthopedic Surgical Procedure

Supportive / Rehabilitative

  • Early speech-language therapy — NCIT:C159273
  • Physical and occupational therapy — NCIT:C15302; NCIT:C121351
  • Individualized Education Programs (IEP) / special education services
  • Feeding therapy
  • Applied Behavior Analysis (ABA) for ASD-related behaviors
  • Cognitive Behavioral Therapy (CBT) for anxiety and social disability — NCIT:C181743 behavioral counseling (proxy)

Genetic Counseling

  • Recommended for all newly diagnosed families given the largely de novo but non-zero recurrence risk and variable expressivity — NCIT:C15240 Genetic Counseling

Experimental / Research-Stage

  • No gene therapy, RNA-based therapy, or targeted molecular therapy currently exists or is in clinical trials for 3q29Del specifically. Mechanistic research (mitochondrial dysfunction, E/I imbalance, ubiquitination pathway) is at the preclinical/model-organism stage and has not yet yielded a therapeutic candidate beyond repurposed psychiatric medications.
  • The mouse model responsiveness to risperidone in normalizing startle/PPI deficits provided early translational rationale for antipsychotic use in this population [Baba et al., Neuropsychopharmacology, 2019, PMID:31216562], though clinical response in humans has proven more variable/resistant than the preclinical data alone would predict.

Treatment Strategy

Care follows a surveillance-and-symptom-management algorithm: baseline multidisciplinary evaluation at diagnosis (developmental, psychiatric, cardiac, ophthalmologic, dental, neuroimaging) → tailored early intervention → longitudinal surveillance (annual neuropsychiatric assessment and scoliosis screening; twice-yearly dental exams; annual ophthalmology) with explicit attention to psychosis-prodrome monitoring through adolescence, particularly around any stimulant initiation.

13. Prevention

Primary Prevention

No primary prevention exists for the de novo NAHR-mediated deletion event itself; there is no known modifiable risk factor to reduce occurrence.

Secondary Prevention (Early Detection)

  • Prenatal diagnosis: possible via chromosomal microarray or genome-wide NIPT if performed for other indications; not part of a standard universal prenatal screening panel.
  • Preimplantation genetic testing (PGT): an option for known carrier parents (the ~7% inherited-case subset) pursuing future pregnancies, analogous to other recurrent CNV syndromes.
  • Early postnatal recognition: prompt CMA testing in infants presenting with feeding difficulty, hypotonia, developmental delay, or congenital heart disease enables earlier initiation of surveillance and intervention.

Tertiary Prevention (Preventing Complications)

  • Structured surveillance protocol (as above) is explicitly designed to catch and mitigate complications early — e.g., early psychosis-prodrome identification to enable earlier intervention, scoliosis screening to catch progressive curvature, and cautious ADHD-medication selection to reduce psychosis-precipitation risk.

Genetic Counseling / Family Planning

  • Central preventive tool for this syndrome: parental testing after a proband diagnosis to establish de novo vs. inherited status, recurrence-risk counseling (50% for a carrier parent; low but non-zero for simplex families due to possible germline mosaicism), and discussion of prenatal/preimplantation testing options for future pregnancies — NCIT:C15240.

Public Health / Behavioral / Screening Programs

Not applicable at a population level — this is a rare, largely non-preventable de novo genomic disorder without an identified environmental trigger, so public-health-level primary prevention strategies (vaccination, exposure reduction) do not apply.

14. Other Species / Natural Disease

3q29 microdeletion syndrome, as a human-specific recurrent CNV defined by human-specific LCR architecture at a human chromosomal locus, has no documented naturally-occurring veterinary/companion-animal counterpart (unlike some single-gene Mendelian disorders with OMIA-catalogued naturally occurring animal analogs). All animal data derive from engineered models, not spontaneous disease (see Model Organisms, below).

  • Taxonomy: Human-specific structural locus; NCBITaxon:9606 (Homo sapiens)
  • Orthologous genes: Mouse orthologs of the human 3q29 interval map to a syntenic region on mouse chromosome 16, bounded by Bdh1 and Tfrc — the region used to engineer the mouse deletion model.
  • No comparative/evolutionary conservation analysis beyond the syntenic mapping used for model construction has been reported.
  • Zoonotic/transmission relevance: Not applicable (non-infectious, structural genomic disorder).

15. Model Organisms

3q29Del is one of the more extensively modeled recurrent CNVs across three complementary experimental systems — mouse, Drosophila/Xenopus, and human iPSC-derived cortical organoids — reflecting active mechanistic research given its status as a top-tier schizophrenia risk locus.

Mouse Models

  1. Baba et al., Neuropsychopharmacology, 2019;44(12):2125–2135 (PMID:31216562) — heterozygous deletion (Df/+) of the syntenic Bdh1–Tfrc interval on mouse chromosome 16 (~1.3 Mb, ~22–24 genes). Recapitulates: impaired prepulse inhibition (schizophrenia-relevant), reduced social interaction (autism-relevant), increased repetitive self-grooming, impaired fear-based learning, elevated acoustic startle. Whole-brain imaging (FAST technology) revealed cortical hyperactivity concentrated in auditory cortex with elevated immediate-early genes and decreased parvalbumin-positive interneuron density, implicating excitatory/inhibitory imbalance. Risperidone rescued the startle/PPI deficits — evidence for translational (pharmacological) validity.
  2. Relationship: RECAPITULATES core psychiatric-relevant behavioral domains; fidelity MODERATE-HIGH for schizophrenia/autism-relevant endophenotypes.

  3. Limitation: Mouse deletion spans a slightly larger/non-identical gene set than the canonical human LCR-flanked interval; not all human phenotypes (e.g., GI, cardiac) are modeled.

  4. CRISPR-engineered mouse model — Rutkowski et al./Molecular Psychiatry, 2019 (PMID:30976085) — independently engineered heterozygous deletion of the syntenic interval via CRISPR/Cas9. Recapitulates reduced body weight (paralleling human failure-to-thrive/reduced birth weight), plus behavioral impairments in social interaction, cognition, acoustic startle, and amphetamine sensitivity.

  5. Relationship: RECAPITULATES growth-deficit and multi-domain behavioral phenotype; fidelity MODERATE.

Invertebrate / Amphibian Models

  1. NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila and Xenopus laevis models — Rump et al./PMC (PLOS Genetics, 2020;16(2):e1008590, PMID:32053595). Systematically tested 14 individual fly/frog homologs of 3q29 genes and 314 pairwise gene-gene interactions for neuronal, cellular, and developmental phenotypes. NCBP2 emerged as a broad genetic enhancer/modifier, exacerbating the developmental phenotypes driven by other 3q29 homologs and disrupting apoptosis and cell-cycle pathways.
  2. Relationship: PERTURBS individual and combinatorial gene function; establishes the oligogenic/two-hit model for the locus.
  3. Follow-on: "Functional assessment of the 'two-hit' model for neurodevelopmental defects in Drosophila and X. laevis" (PMC8049494) directly tests combinatorial (two-gene) haploinsufficiency phenotypes.
  4. Limitation: Invertebrate/amphibian systems necessarily diverge substantially from human neurodevelopmental and psychiatric circuitry — useful for high-throughput gene-gene interaction screening rather than direct behavioral phenocopy.

Human Cellular Models

  1. iPSC-derived cortical organoids — used in "Convergent and distributed effects of the 3q29 deletion on the human neural transcriptome" (Transl Psychiatry, 2021;11:344) and the cross-species mitochondrial-dysregulation study (Purcell/Sefik et al., Sci Adv, 2023;9(33):eadh0558, PMID:37585521). Single-cell RNA-seq of isogenic cortical organoids (2 and 12 months) alongside mouse isocortex identified 176 concordantly differentially-expressed genes in excitatory neurons across species, converging on mitochondrial function and energy metabolism, with functional assays confirming reduced metabolic flexibility and implicating PAK2 as a contributor.
  2. Relationship: RECAPITULATES transcriptomic/metabolic dysregulation at the cellular level in a genetically human, isogenic system; fidelity HIGH for molecular convergence, though behavioral/circuit-level correlates cannot be assessed in vitro.
  3. This is the most human-proximal model system currently available and is central to current mechanistic hypotheses (mitochondrial dysfunction as a convergent node).

Model Resources

No dedicated 3q29Del strain is yet cataloged in IMPC/KOMP as a validated multi-gene deletion allele (the model lines described above are investigator-generated, not centrally banked); individual single-gene knockout alleles for Dlg1, Pak2, etc., are available through MGI/IMSR but explicitly do not recapitulate the full syndrome, reinforcing the combinatorial/oligogenic model.

Summary of Suggested Ontology Term Bindings for KB Curation

Category Suggested term
Disease MONDO:0012269 (chromosome 3q29 microdeletion syndrome); OMIM:609425
Causal genes hgnc:2905 (DLG1), hgnc:8591 (PAK2), hgnc:7647 (NCBP2), hgnc:20620 (RNF168), hgnc:24129 (FBXO45), hgnc:29076 (UBXN7), hgnc:20351 (SENP5)
Key phenotypes (HP) HP:0001263 (global developmental delay), HP:0001256 (mild ID), HP:0000729 (autistic behavior), HP:0007018 (ADHD), HP:0000739 (anxiety), HP:0000709 (psychosis), HP:0002020 (GERD), HP:0002019 (constipation), HP:0001508 (failure to thrive), HP:0001321 (cerebellar hypoplasia), HP:0002571 (retrocerebellar cyst), HP:0001631/HP:0001643 (cardiac defects), HP:0000486 (strabismus)
GO biological processes GO:0007268 (chemical synaptic transmission), GO:0030036 (actin cytoskeleton organization), GO:0016567 (protein ubiquitination), GO:0006119 (oxidative phosphorylation)
CL cell types CL:0000679 (glutamatergic neuron), CL:0000846 (parvalbumin GABAergic interneuron)
UBERON UBERON:0002037 (cerebellum), UBERON:0001950 (neocortex), UBERON:0000948 (heart)
NCIT treatments NCIT:C15986 (Pharmacotherapy), NCIT:C15302 (Physical Therapy), NCIT:C15240 (Genetic Counseling), NCIT:C15329 (Surgical Procedure)

Key Primary Citations (PMID-referenced)

  1. Willatt L, et al. "3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome." Am J Hum Genet. 2005;77(1):154–160. PMID:15918153
  2. Mulle JG, et al. "Microdeletions of 3q29 confer high risk for schizophrenia." Am J Hum Genet. 2010;87(2):229–236. PMID:20691406
  3. Mulle JG. "The 3q29 deletion confers >40-fold increase in risk for schizophrenia." Mol Psychiatry. 2015;20:1028–1029. PMID:26055425
  4. Sanchez Russo R, et al. "Deep phenotyping in 3q29 deletion syndrome: recommendations for clinical care." Genet Med. 2021;23(5):872–880. PMID:33564151
  5. Pollak RM, et al. "Neuropsychiatric phenotypes and a distinct constellation of ASD features in 3q29 deletion syndrome: results from the 3q29 registry." Mol Autism. 2019;10:30. PMID:31346402
  6. Rump P, et al. "NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila and Xenopus laevis models." PLoS Genet. 2020;16(2):e1008590. PMID:32053595
  7. Baba M, et al. "Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome." Neuropsychopharmacology. 2019;44(12):2125–2135. PMID:31216562
  8. Rutkowski TP, et al. "Behavioral changes and growth deficits in a CRISPR engineered mouse model of the schizophrenia-associated 3q29 deletion." Mol Psychiatry. 2019. PMID:30976085
  9. Purcell RH, Sefik E, et al. "Cross-species analysis identifies mitochondrial dysregulation as a functional consequence of the schizophrenia-associated 3q29 deletion." Sci Adv. 2023;9(33):eadh0558. PMID:37585521
  10. Oetjens MT, et al. "Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders." Nat Commun. 2019;10:4897.
  11. Klaiman C, et al. "A distinct cognitive profile in individuals with 3q29 deletion syndrome." J Intellect Disabil Res. 2023. PMID:35297118
  12. Sanders A, et al. "Structural deviations of the posterior fossa and the cerebellum and their cognitive links in a neurodevelopmental deletion syndrome." Mol Psychiatry. 2024. PMID:38744992
  13. "Driver or passenger? A new assessment of genes in the schizophrenia-associated 3q29 deletion locus for contribution to neurodevelopmental disorders." J Neurodevelopmental Disord. 2026;18. (PMID pending indexing at time of report)
  14. "Response to Treatment in 3q29 Deletion Syndrome-Associated Psychosis: A Mini-Review." Neuropsychobiology. 2026;82(5):263. (Karger)

Note on data gaps: No syndrome-specific standardized QoL instrument data, no confirmed epigenetic/methylation signature, no naturally-occurring veterinary analog, and no disease-modifying/targeted therapy currently exist in the published literature — these should be flagged as NOT_AVAILABLE/absent rather than inferred in any downstream knowledge base entry.

Sources: - chromosome 3q29 microdeletion syndrome - NORD - 3q29 Recurrent Deletion - GeneReviews® - OMIM #609425 - OMIM #611936 - Monarch Initiative MONDO:0012269 - Willatt et al. 2005, PubMed - Mulle et al. 2010, PMC - The 3q29 deletion confers >40-fold increase in risk for schizophrenia, Molecular Psychiatry - Deep phenotyping in 3q29 deletion syndrome, PMC - Neuropsychiatric phenotypes and ASD features, 3q29 registry, PMC - Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model, PMC - Behavioral changes and growth deficits in a CRISPR engineered mouse model, PMC - NCBP2 modulates neurodevelopmental defects, PLOS Genetics - Structural deviations of the posterior fossa and cerebellum, PMC - Cross-species analysis identifies mitochondrial dysregulation, Science Advances - Driver or passenger? A new assessment of genes in the 3q29 locus, J Neurodevelopmental Disorders - A distinct cognitive profile in individuals with 3q29 deletion syndrome, medRxiv - Response to Treatment in 3q29 Deletion Syndrome-Associated Psychosis, Karger - Early-onset psychosis as a sentinel manifestation of 3q29 deletion syndrome, Frontiers - 3q29 Recurrent Deletion Table B, GeneReviews - About Us, 3q29 Project, Emory - Study protocol for The Emory 3q29 Project, PubMed - Phenotype Heterogeneity in 3q29 Microduplication Syndrome, PMC

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 25
Resolved 25
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 2
Quoted claims found in source 2

All extracted references resolved successfully.